Multicistronic RNA vaccines and uses thereof
Patent Information
- Application Number
- JP2023534301
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-02
- Filing Date
- 2021-12-02
- Publication Date
- 2024-11-07
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current respiratory viral infections, such as influenza and COVID-19, lack effective treatments and vaccines that can be produced quickly and efficiently, with existing mRNA vaccines facing challenges in stability and antigen expression, and egg-based manufacturing processes being time-consuming and resource-intensive.
Development of multicistronic RNA vaccines, including self-replicating and conventional mRNA, utilizing regulatory elements like subgenomic promoters and internal ribosome entry sites (IRES) to efficiently express multiple antigens, enhancing stability and immune response.
The multicistronic RNA vaccines provide improved antigen expression and stability, enabling rapid production of effective vaccines against respiratory viral infections, overcoming limitations of existing technologies.
Smart Images

Figure 00000130_0000 
Figure 00000130_0001 
Figure 00000131_0000
Abstract
Description
[Technical Field]
[0001] Related application data This application claims priority from U.S. Patent Application No. 63 / 120,362, entitled "Multicistronic self-replicating RNA and uses thereof," filed December 2, 2020, the entire contents of which are incorporated herein by reference.
[0002] Array List This application is filed with a Sequence Listing in electronic form, the entire contents of which are incorporated herein by reference.
[0003] The present disclosure relates to multicistronic RNA vaccines and uses thereof. The present disclosure also relates to multicistronic conventional mRNA vaccines and uses thereof. The present disclosure further relates to multicistronic self-replicating RNA vaccines and uses thereof. [Background technology]
[0004] Respiratory viral infections pose a serious threat to human health and life. Infections such as those caused by influenza viruses and severe acute respiratory syndrome coronavirus (SARS-CoV) are known to cause global pandemics, killing millions of people worldwide. Recently, SAR-CoV-2 has been implicated in the ongoing global pandemic of severely infectious coronavirus disease 2019 (COVID-19).
[0005] Currently, infections such as influenza are treated with antiviral or other drugs. However, currently, there are no specific and effective treatments for most respiratory viral infections. Specific treatments available for some respiratory viral infections, such as mRNA vaccines for COVID-19, can be further improved to increase their effectiveness.
[0006] Viral vaccines, such as those for influenza, rely on the induction of antibodies that protect against infection by neutralizing the virus or blocking its entry into cells. The humoral immune response targets viral surface proteins; however, these surface proteins are conserved within each strain, making antibody-mediated protection incompatible with strains with serologically distinct surface proteins. Furthermore, the surface proteins of many viruses can mutate rapidly. This means that most vaccines must be multivalent, i.e., contain antigens from strains predicted to be most prevalent within a given period of time.
[0007] Various adjuvants and immunopotentiators are included in vaccine formulations to enhance immune responses (e.g., antibody responses) induced by influenza virus surface proteins, but safety and efficacy issues remain.
[0008] Currently, egg-based manufacturing processes are the most common way influenza vaccines are produced. This process requires significant time to optimize virus growth in eggs and requires resources (i.e., eggs) to produce sufficient quantities of vaccine, especially during a pandemic. Furthermore, given the long development time required, vaccine strain selection occurs before a vaccine is available, making it difficult to respond to changes in the virus. Influenza vaccines have also been produced using cell-based manufacturing processes involving cultured mammalian cells (e.g., Madin-Darby canine kidney, or MDCK, cells) instead of eggs, and virus-based platforms involving recombinant viruses (e.g., baculoviruses encoding influenza antigens).
[0009] There remains a need for the development of specific and efficient viral vaccines that can be produced more quickly than current egg-based technologies for the treatment or prevention of respiratory viral infections, such as influenza and COVID-19. While nucleic acid-based vaccines offer clear advantages over current egg-based manufacturing platforms, several challenges remain. For example, the inherently unstable nature of mRNA results in most RNA-based vaccines being limited in their ability to provide antigens at the doses and durations required to generate a strong and durable immune response. Therefore, it will be apparent to those skilled in the art that there is a need in the art for improved means for delivering exogenous nucleic acids to a subject. There is also a need in the art for mRNA vaccines with enhanced stability and improved antigen expression within a subject's target cells. Summary of the Invention [Means for solving the problem]
[0010] The inventors of the present disclosure have identified RNAs that have improved activity and allow for efficient expression of two or more antigens (i.e., multicistronic RNAs). The present disclosure is based on the inventors' identification of self-replicating RNAs with improved activity. In particular, the inventors have identified self-replicating RNAs that allow for efficient expression of two or more antigens and do not result in the formation of undesired fusion proteins.
[0011] The findings of the present inventors provide a basis for multicistronic RNA. The findings of the present inventors also provide a basis for multicistronic self-replicating RNA. Furthermore, the findings of the present inventors provide a basis for multicistronic conventional (i.e., non-self-replicating) RNA. The findings of the present inventors also provide a basis for methods of treating, preventing, or delaying the progression of a disease or disorder in a subject (e.g., a disease caused by a respiratory virus infection such as influenza, SARS-COV-2 infection, COVID-19, or ARDS).
[0012] Accordingly, the present disclosure provides a polynucleotide comprising: a) a first nucleotide sequence encoding a first polypeptide of interest; and b) a second nucleotide sequence encoding a second polypeptide of interest operably linked to a regulatory element selected from the group consisting of a subgenomic (SG) promoter and an internal ribosome entry site (IRES).
[0013] In one example, the polynucleotide comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first polypeptide of interest; and b) a second nucleotide sequence encoding a second polypeptide of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0014] The present disclosure also provides a polynucleotide comprising: a) a first nucleotide sequence encoding a first antigen of interest; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0015] In one example, the polynucleotide comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen of interest; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0016] In one embodiment, the polynucleotide is RNA or DNA. For example, the polynucleotide is RNA. In one embodiment, the polynucleotide is DNA.
[0017] In one embodiment, the RNA is messenger RNA (mRNA). In one embodiment, the mRNA is conventional mRNA (cRNA) or self-replicating mRNA.
[0018] Thus, the present disclosure provides an RNA comprising: a) a first nucleotide sequence encoding a first antigen of interest; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0019] In one example, the RNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen of interest; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0020] The present disclosure also provides a cRNA comprising: a) a first nucleotide sequence encoding a first antigen of interest; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0021] In one example, the cRNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen of interest; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0022] The present disclosure further provides a self-replicating mRNA comprising: a) a first nucleotide sequence encoding a first antigen of interest, and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0023] In one example, the self-replicating mRNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen of interest; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0024] In one embodiment, the first nucleotide sequence encoding the first antigen of interest is operably linked to a regulatory element. For example, the regulatory element is operably linked to the 5' end of the first nucleotide sequence. In one embodiment, the regulatory element is selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof. For example, the regulatory element is a Kozak consensus sequence. For example, the regulatory element is an IRES. For example, the regulatory element is an SG promoter.
[0025] In one embodiment, the Kozak consensus sequence comprises or consists of the sequence set forth in SEQ ID NO: 38. In one embodiment, the Kozak consensus sequence consists of the sequence set forth in SEQ ID NO: 38. In one embodiment, the Kozak consensus sequence comprises the sequence set forth in SEQ ID NO: 38. For example, the Kozak consensus sequence is ACCATGG.
[0026] In one embodiment, the Kozak consensus sequence comprises or consists of the sequence set forth in SEQ ID NO: 39. In one embodiment, the Kozak consensus sequence consists of the sequence set forth in SEQ ID NO: 39. In one embodiment, the Kozak consensus sequence comprises the sequence set forth in SEQ ID NO: 39. For example, the Kozak consensus sequence is ACCATG.
[0027] The present disclosure provides a polynucleotide comprising: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0028] In one example, the polynucleotide comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0029] The present disclosure provides an RNA comprising: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0030] In one example, the RNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0031] The present disclosure provides a cRNA comprising: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0032] In one example, the cRNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0033] The present disclosure provides a self-replicating mRNA comprising: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0034] In one example, the self-replicating mRNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0035] In one example, a first nucleotide sequence encoding a first antigen of interest is operably linked to a Kozak consensus sequence.
[0036] In one example, a first nucleotide sequence encoding a first antigen of interest is operably linked to a Kozak consensus sequence and an SG promoter, e.g., the Kozak consensus sequence is operably linked to the 5' end of an SG promoter, which is operably linked to the 5' end of the first nucleotide sequence encoding the first antigen of interest.
[0037] In one example, a first nucleotide sequence encoding a first antigen of interest is operably linked to a Kozak consensus sequence and an IRES, e.g., the Kozak consensus sequence is operably linked to the 5' end of an IRES, which is operably linked to the 5' end of the first nucleotide sequence encoding the first antigen of interest.
[0038] In one example, a first nucleotide sequence encoding a first antigen of interest is operably linked to an SG promoter.
[0039] In one example, the first nucleotide sequence encoding the first antigen of interest is operably linked to an IRES.
[0040] The present disclosure provides a polynucleotide comprising: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0041] In one example, the polynucleotide comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0042] The present disclosure provides a polynucleotide comprising: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0043] In one example, the polynucleotide comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0044] The present disclosure provides a polynucleotide comprising: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a Kozak consensus sequence and an IRES, and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0045] In one example, the polynucleotide comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0046] The present disclosure provides a polynucleotide comprising: a) a first nucleotide sequence encoding a first antigen of interest operably linked to an SG promoter; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0047] In one example, the polynucleotide comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen of interest operably linked to an SG promoter; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0048] The present disclosure provides a polynucleotide comprising: a) a first nucleotide sequence encoding a first antigen of interest operably linked to an IRES, and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0049] In one example, the polynucleotide comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen of interest operably linked to an IRES; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0050] The present disclosure provides an RNA comprising: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0051] In one example, the RNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0052] The present disclosure provides an RNA comprising: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0053] In one example, the RNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0054] The present disclosure provides an RNA comprising: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a Kozak consensus sequence and an IRES, and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0055] In one example, the RNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0056] The present disclosure provides an RNA comprising: a) a first nucleotide sequence encoding a first antigen of interest operably linked to an SG promoter; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0057] In one example, the RNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen of interest operably linked to an SG promoter; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0058] The present disclosure provides an RNA comprising: a) a first nucleotide sequence encoding a first antigen of interest operably linked to an IRES, and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0059] In one example, the RNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen of interest operably linked to an IRES; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0060] The present disclosure provides a cRNA comprising: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0061] In one example, the cRNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0062] The present disclosure provides a cRNA comprising: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0063] In one example, the cRNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0064] The present disclosure provides a cRNA comprising: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a Kozak consensus sequence and an IRES, and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0065] In one example, the cRNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen of interest operably linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0066] The present disclosure provides a cRNA comprising: a) a first nucleotide sequence encoding a first antigen of interest operably linked to an SG promoter; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0067] In one example, the cRNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen of interest operably linked to an SG promoter; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0068] The present disclosure provides a cRNA comprising: a) a first nucleotide sequence encoding a first antigen of interest operably linked to an IRES, and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0069] In one example, the cRNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen of interest operably linked to an IRES; and b) a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0070] The present disclosure provides a multicistronic self-replicating RNA comprising: a) a first nucleotide sequence encoding a first antigen operably linked to a subgenomic (SG) promoter; and b) a second nucleotide sequence encoding a second antigen operably linked to a regulatory element selected from the group consisting of an SG promoter and an internal ribosome entry site (IRES).
[0071] In one example, a multicistronic self-replicating RNA of the present disclosure comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter; and b) a second nucleotide sequence encoding a second antigen operably linked to an IRES or an SG promoter.
[0072] In one embodiment, the polynucleotide is a bicistronic RNA. For example, the polynucleotide is a bicistronic cRNA. In one embodiment, the cRNA is a bicistronic cRNA. In another embodiment, the polynucleotide is a bicistronic self-replicating mRNA. For example, the self-replicating RNA is a bicistronic self-replicating RNA.
[0073] In one example, the second nucleotide sequence encoding the second antigen is operably linked to an IRES.
[0074] In one example, a second nucleotide sequence encoding a second antigen is operably linked to an SG promoter.
[0075] In one embodiment, the polynucleotide is a multicistronic RNA. For example, the polynucleotide is a multicistronic cRNA. For example, the cRNA is a multicistronic cRNA. In another embodiment, the polynucleotide is a multicistronic self-replicating mRNA. For example, the self-replicating RNA is a multicistronic self-replicating mRNA.
[0076] In one example, the polynucleotide comprises one or more additional nucleotide sequences, each encoding an additional antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and wherein the one or more nucleotide sequences are located 3' to a second nucleotide sequence. For example, the polynucleotide comprises at least three nucleotide sequences, or at least four nucleotide sequences, or at least five nucleotide sequences, each encoding an antigen.
[0077] In one example, the multicistronic RNA comprises one or more additional nucleotide sequences, each encoding an additional antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and wherein the one or more nucleotide sequences are located 3' to a second nucleotide sequence. For example, the multicistronic RNA comprises at least three nucleotide sequences, or at least four nucleotide sequences, or at least five nucleotide sequences, each encoding an antigen.
[0078] In one example, the multicistronic cRNA comprises one or more additional nucleotide sequences, each encoding an additional antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and the one or more nucleotide sequences are located 3' to a second nucleotide sequence. For example, the multicistronic cRNA comprises at least three nucleotide sequences, or at least four nucleotide sequences, or at least five nucleotide sequences, each encoding an antigen.
[0079] In one example, the multicistronic self-replicating RNA comprises one or more additional nucleotide sequences, each encoding an additional antigen operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and the one or more nucleotide sequences encoding the additional antigens are located 3' to a second nucleotide sequence encoding a second antigen. For example, the multicistronic self-replicating RNA comprises at least three nucleotide sequences, or at least four nucleotide sequences, or at least five nucleotide sequences, each encoding an antigen.
[0080] In one example, the polynucleotide comprises at least three nucleotide sequences, each nucleotide sequence encoding an antigen.
[0081] In one example, the multicistronic RNA comprises at least three nucleotide sequences, each encoding an antigen, e.g., the RNA is a tricistronic RNA.
[0082] In one example, the multicistronic cRNA comprises at least three nucleotide sequences, each encoding an antigen, e.g., the cRNA is a tricistronic RNA.
[0083] In one example, the multicistronic self-replicating RNA comprises at least three nucleotide sequences, each encoding an antigen, e.g., the self-replicating RNA is a tricistronic self-replicating RNA.
[0084] In one example, the polynucleotide comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES or SG promoter; and c) a third nucleotide sequence encoding a third antigen operably linked to an IRES or SG promoter.
[0085] In one example, the multicistronic RNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES or SG promoter; and c) a third nucleotide sequence encoding a third antigen operably linked to an IRES or SG promoter.
[0086] In one example, the multicistronic cRNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES or SG promoter; and c) a third nucleotide sequence encoding a third antigen operably linked to an IRES or SG promoter.
[0087] In one example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES or SG promoter; and c) a third nucleotide sequence encoding a third antigen operably linked to an IRES or SG promoter.
[0088] In one example, the multicistronic self-replicating RNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES or SG promoter; and c) a third nucleotide sequence encoding a third antigen operably linked to an IRES or SG promoter.
[0089] In one example, the polynucleotide comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, and c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter. In another example, the polynucleotide comprises, in 5' to 3' order, a) a first nucleotide sequence encoding the first antigen, b) a second nucleotide sequence encoding the second antigen operably linked to an IRES, and c) a third nucleotide sequence encoding the third antigen operably linked to an IRES.
[0090] In one example, the multicistronic RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, and c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter. In another example, the multicistronic RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, and c) a third nucleotide sequence encoding a third antigen operably linked to an IRES.
[0091] In one example, the multicistronic cRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, and c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter. In another example, the multicistronic cRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, and c) a third nucleotide sequence encoding a third antigen operably linked to an IRES.
[0092] In one example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, and c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter. In another example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, and c) a third nucleotide sequence encoding a third antigen operably linked to an IRES.
[0093] In one example, the multicistronic self-replicating RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, and c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter. In another example, the multicistronic self-replicating RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, and c) a third nucleotide sequence encoding a third antigen operably linked to an IRES.
[0094] In another example, the polynucleotide comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, and c) a third nucleotide sequence encoding a third antigen operably linked to an IRES. In another example, the polynucleotide comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, and c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter.
[0095] In another example, the multicistronic RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, and c) a third nucleotide sequence encoding a third antigen operably linked to an IRES. In another example, the multicistronic RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, and c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter.
[0096] In another example, the multicistronic cRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, and c) a third nucleotide sequence encoding a third antigen operably linked to an IRES. In another example, the multicistronic cRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, and c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter.
[0097] In another example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, and c) a third nucleotide sequence encoding a third antigen operably linked to an IRES. In another example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, and c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter.
[0098] In another example, the multicistronic self-replicating RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, and c) a third nucleotide sequence encoding a third antigen operably linked to an IRES. In another example, the multicistronic self-replicating RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, and c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter.
[0099] In one example, the polynucleotide comprises at least four nucleotide sequences, each nucleotide sequence encoding an antigen.
[0100] In one example, the multicistronic RNA comprises at least four nucleotide sequences, each nucleotide sequence encoding an antigen.
[0101] In one example, the multicistronic cRNA comprises at least four nucleotide sequences, each of which encodes an antigen.
[0102] In one example, the multicistronic self-replicating RNA comprises at least four nucleotide sequences, each nucleotide sequence encoding an antigen.
[0103] In one example, the polynucleotide comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES or SG promoter; c) a third nucleotide sequence encoding a third antigen operably linked to an IRES or SG promoter; and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES or SG promoter.
[0104] In one example, the multicistronic RNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES or SG promoter; c) a third nucleotide sequence encoding a third antigen operably linked to an IRES or SG promoter; and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES or SG promoter.
[0105] In one example, the multicistronic cRNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES or SG promoter; c) a third nucleotide sequence encoding a third antigen operably linked to an IRES or SG promoter; and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES or SG promoter.
[0106] In one example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES or SG promoter; c) a third nucleotide sequence encoding a third antigen operably linked to an IRES or SG promoter; and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES or SG promoter.
[0107] In one example, the multicistronic self-replicating RNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES or SG promoter; c) a third nucleotide sequence encoding a third antigen operably linked to an IRES or SG promoter; and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES or SG promoter.
[0108] In one example, the polynucleotide comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter, and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter. In another example, the polynucleotide comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, and d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an SG promoter. In a further example, the polynucleotide comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter. In another example, the polynucleotide comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, and d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an IRES.
[0109] In one example, the multicistronic RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter, and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter. In another example, the multicistronic RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, and d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an SG promoter. In a further example, the multicistronic RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter. In another example, the multicistronic RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, and d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an IRES.
[0110] In one example, the multicistronic cRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter, and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter. In another example, the multicistronic cRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, and d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an SG promoter. In a further example, the multicistronic cRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter. In another example, the multicistronic cRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, and d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an IRES.
[0111] In one example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter, and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter. In another example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, and d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an SG promoter. In a further example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter. In another example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, and d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an IRES.
[0112] In one example, the multicistronic self-replicating RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter, and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter. In another example, the multicistronic self-replicating RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, and d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an SG promoter. In a further example, the multicistronic self-replicating RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter. In another example, the multicistronic self-replicating RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES.
[0113] In one example, the polynucleotide comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter. In another example, the polynucleotide comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, and d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an IRES.
[0114] In one example, the multicistronic RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter. In another example, the multicistronic RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, and d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an IRES.
[0115] In one example, the multicistronic cRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter. In another example, the multicistronic cRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, and d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an IRES.
[0116] In one example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter. In another example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, and d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an IRES.
[0117] In one example, the multicistronic self-replicating RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter. In another example, the multicistronic self-replicating RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES.
[0118] In one example, the polynucleotide comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES. In a further example, the polynucleotide comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding the third antigen operably linked to an IRES, and d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an IRES.
[0119] In one example, the multicistronic RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES. In a further example, the multicistronic RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding the third antigen operably linked to an IRES, and d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an IRES.
[0120] In one example, the multicistronic cRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES. In a further example, the multicistronic cRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding the third antigen operably linked to an IRES, and d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an IRES.
[0121] In one example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES. In a further example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding the third antigen operably linked to an IRES, and d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an IRES.
[0122] In one example, the multicistronic self-replicating RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES. In a further example, the multicistronic self-replicating RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding the third antigen operably linked to an IRES, and d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES.
[0123] In one example, the polynucleotide comprises at least five nucleotide sequences, each nucleotide sequence encoding an antigen.
[0124] In one example, the multicistronic RNA comprises at least five nucleotide sequences, each nucleotide sequence encoding an antigen.
[0125] In one example, the multicistronic cRNA comprises at least five nucleotide sequences, each nucleotide sequence encoding an antigen.
[0126] In one example, the multicistronic self-replicating RNA comprises at least five nucleotide sequences, each nucleotide sequence encoding an antigen.
[0127] In one example, the polynucleotide comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES or SG promoter; c) a third nucleotide sequence encoding a third antigen operably linked to an IRES or SG promoter; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES or SG promoter; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES or SG promoter.
[0128] In one example, the multicistronic RNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES or SG promoter; c) a third nucleotide sequence encoding a third antigen operably linked to an IRES or SG promoter; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES or SG promoter; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES or SG promoter.
[0129] In one example, the multicistronic cRNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES or SG promoter; c) a third nucleotide sequence encoding a third antigen operably linked to an IRES or SG promoter; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES or SG promoter; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES or SG promoter.
[0130] In one example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES or SG promoter; c) a third nucleotide sequence encoding a third antigen operably linked to an IRES or SG promoter; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES or SG promoter; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES or SG promoter.
[0131] In one example, the multicistronic self-replicating RNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES or SG promoter; c) a third nucleotide sequence encoding a third antigen operably linked to an IRES or SG promoter; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES or SG promoter; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES or SG promoter.
[0132] In one example, the polynucleotide comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter, d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter, and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter. In another example, the polynucleotide comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an SG promoter, and e) a fifth nucleotide sequence encoding the fifth antigen operably linked to an SG promoter. In a further example, the polynucleotide comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter, and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter. In another example, the polynucleotide comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an IRES, and e) a fifth nucleotide sequence encoding the fifth antigen operably linked to an SG promoter.In a further example, the polynucleotide comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter; c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES.
[0133] In one example, the multicistronic RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter, d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter, and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter. In another example, the multicistronic RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an SG promoter, and e) a fifth nucleotide sequence encoding the fifth antigen operably linked to an SG promoter. In a further example, the multicistronic RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter, and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter. In another example, the multicistronic RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an IRES, and e) a fifth nucleotide sequence encoding the fifth antigen operably linked to an SG promoter.In a further example, the multicistronic RNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter; c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES.
[0134] In one example, the multicistronic cRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter, d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter, and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter. In another example, the multicistronic cRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an SG promoter, and e) a fifth nucleotide sequence encoding the fifth antigen operably linked to an SG promoter. In a further example, the multicistronic cRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter, and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter. In another example, the multicistronic cRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an IRES, and e) a fifth nucleotide sequence encoding the fifth antigen operably linked to an SG promoter.In a further example, the multicistronic cRNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter; c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES.
[0135] In one example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter, d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter, and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter. In another example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an SG promoter, and e) a fifth nucleotide sequence encoding the fifth antigen operably linked to an SG promoter. In a further example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter, and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter. In another example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an IRES, and e) a fifth nucleotide sequence encoding the fifth antigen operably linked to an SG promoter.In a further embodiment, the multicistronic self-replicating mRNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter; c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES.
[0136] In one example, the multicistronic self-replicating RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter, d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter, and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter. In another example, the multicistronic self-replicating RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an SG promoter, and e) a fifth nucleotide sequence encoding the fifth antigen operably linked to an SG promoter. In a further embodiment, the multicistronic self-replicating RNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter; b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter; c) a third nucleotide sequence encoding a third antigen operably linked to an IRES; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter.In another example, the multicistronic self-replicating RNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter; b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter; c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter. In a further embodiment, the multicistronic self-replicating RNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter; b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter; c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES.
[0137] In one example, the polynucleotide comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter, and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter. In another example, the polynucleotide comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an IRES, and e) a fifth nucleotide sequence encoding the fifth antigen operably linked to an SG promoter. In a further example, the polynucleotide comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES; c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES.
[0138] In one example, the multicistronic RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter, and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter. In another example, the multicistronic RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an IRES, and e) a fifth nucleotide sequence encoding the fifth antigen operably linked to an SG promoter. In a further example, the multicistronic RNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES; c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES.
[0139] In one example, the multicistronic cRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter, and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter. In another example, the multicistronic cRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an IRES, and e) a fifth nucleotide sequence encoding the fifth antigen operably linked to an SG promoter. In a further example, the multicistronic cRNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES; c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES.
[0140] In one example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter, and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter. In another example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an IRES, and e) a fifth nucleotide sequence encoding the fifth antigen operably linked to an SG promoter. In a further embodiment, the multicistronic self-replicating mRNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES; c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES.
[0141] In one example, the multicistronic self-replicating RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter, and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter. In another example, the multicistronic self-replicating RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding the third antigen operably linked to an SG promoter, d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an IRES, and e) a fifth nucleotide sequence encoding the fifth antigen operably linked to an SG promoter. In a further embodiment, the multicistronic self-replicating RNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES; c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an SG promoter; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES.
[0142] In one example, the polynucleotide comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES, and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter. In another example, the polynucleotide comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding the third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an SG promoter, and e) a fifth nucleotide sequence encoding the fifth antigen operably linked to an IRES. In a further example, the polynucleotide comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter; c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES.
[0143] In one example, the multicistronic RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES, and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter. In another example, the multicistronic RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding the third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an SG promoter, and e) a fifth nucleotide sequence encoding the fifth antigen operably linked to an IRES. In a further example, the multicistronic RNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter; c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES.
[0144] In one example, the multicistronic cRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES, and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter. In another example, the multicistronic cRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding the third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an SG promoter, and e) a fifth nucleotide sequence encoding the fifth antigen operably linked to an IRES. In a further example, the multicistronic cRNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter; c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES.
[0145] In one example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES, and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter. In another example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding the third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an SG promoter, and e) a fifth nucleotide sequence encoding the fifth antigen operably linked to an IRES. In a further embodiment, the multicistronic self-replicating mRNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter; c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES.
[0146] In one example, the multicistronic self-replicating RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES, and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter. In another example, the multicistronic self-replicating RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding the third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an SG promoter, and e) a fifth nucleotide sequence encoding the fifth antigen operably linked to an IRES. In a further embodiment, the multicistronic self-replicating RNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter; b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter; c) a third nucleotide sequence encoding a third antigen operably linked to an SG promoter; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES.
[0147] In one example, the polynucleotide comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES, and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter. In another example, the polynucleotide comprises, in 5' to 3' order, a) a first nucleotide sequence encoding the first antigen, b) a second nucleotide sequence encoding the second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding the third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an IRES, and e) a fifth nucleotide sequence encoding the fifth antigen operably linked to an IRES.
[0148] In one example, the multicistronic RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES, and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter. In another example, the multicistronic RNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding the third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an IRES, and e) a fifth nucleotide sequence encoding the fifth antigen operably linked to an IRES.
[0149] In one example, the multicistronic cRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES, and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter. In another example, the multicistronic cRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding the third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an IRES, and e) a fifth nucleotide sequence encoding the fifth antigen operably linked to an IRES.
[0150] In one example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an IRES, c) a third nucleotide sequence encoding a third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES, and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter. In another example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order, a) a first nucleotide sequence encoding a first antigen, b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter, c) a third nucleotide sequence encoding the third antigen operably linked to an IRES, d) a fourth nucleotide sequence encoding the fourth antigen operably linked to an IRES, and e) a fifth nucleotide sequence encoding the fifth antigen operably linked to an IRES.
[0151] In one example, the multicistronic self-replicating RNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES; c) a third nucleotide sequence encoding a third antigen operably linked to an IRES; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an SG promoter. In another example, the multicistronic self-replicating RNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter; b) a second nucleotide sequence encoding a second antigen operably linked to an SG promoter; c) a third nucleotide sequence encoding a third antigen operably linked to an IRES; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES.
[0152] In one example, the polynucleotide comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES; c) a third nucleotide sequence encoding a third antigen operably linked to an IRES; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES.
[0153] In one example, the multicistronic RNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES; c) a third nucleotide sequence encoding a third antigen operably linked to an IRES; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES.
[0154] In one example, the multicistronic cRNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES; c) a third nucleotide sequence encoding a third antigen operably linked to an IRES; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES.
[0155] In one example, the multicistronic self-replicating mRNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES; c) a third nucleotide sequence encoding a third antigen operably linked to an IRES; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES.
[0156] In one example, the multicistronic self-replicating RNA comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen operably linked to an SG promoter; b) a second nucleotide sequence encoding a second antigen operably linked to an IRES; c) a third nucleotide sequence encoding a third antigen operably linked to an IRES; d) a fourth nucleotide sequence encoding a fourth antigen operably linked to an IRES; and e) a fifth nucleotide sequence encoding a fifth antigen operably linked to an IRES.
[0157] In one embodiment, the SG promoter is a native SG promoter. For example, a native SG promoter is a promoter native to an RNA virus derived from and / or based on an RNA virus (e.g., an alphavirus). In one embodiment, the native SG promoter is a native alphavirus SG promoter.
[0158] In one embodiment, the SG promoter is a minimal SG promoter or an extended SG promoter.
[0159] In one embodiment, the SG promoter is a minimal SG promoter. In one embodiment, the native SG promoter is a minimal SG promoter. For example, a minimal SG promoter is the minimal sequence required for initiation of transcription. In one embodiment, the minimal native SG promoter is 49 nucleotides in length. In one embodiment, the minimal SG promoter is 49 nucleotides in length. In one embodiment, the minimal native SG promoter is encoded by a sequence comprising or consisting of the sequence set forth in SEQ ID NO: 1. In one embodiment, the minimal SG promoter is encoded by a sequence comprising or consisting of the sequence set forth in SEQ ID NO: 1.
[0160] In one embodiment, the SG promoter is an extended SG promoter. In one embodiment, the native SG promoter is an extended SG promoter. For example, the extended SG promoter is extended at the 5' end by nucleotides that occur in the sequence encoding a nonstructural protein (e.g., NSP4) of an RNA virus (e.g., an alphavirus). In one embodiment, the extended SG promoter is extended at the 5' end by nucleotides that occur in the sequence encoding alphavirus NSP4. The addition of nucleotides to the 5' end of the SG promoter sequence did not inhibit expression of the nonstructural protein and viral replicase, e.g., alphavirus NSP4.
[0161] Surprisingly, the present inventors have found that the number of nucleotides added to the 5' end of an SG promoter to enhance expression is limited. For example, the present inventors have found that an SG promoter extended at its 5' end by 52 nucleotides occurring in the sequence encoding a nonstructural protein (e.g., alphavirus NSP4) does not function. Notably, no antigen expression was detected when an SG promoter extended at its 5' end by 52 nucleotides occurring in the sequence encoding a nonstructural protein (e.g., alphavirus NSP4) was used. Thus, in one embodiment, the SG promoter is extended at its 5' end by 51 or fewer nucleotides occurring in the sequence encoding a nonstructural protein (e.g., alphavirus NSP4). In one embodiment, the extended SG promoter is a minimal SG promoter extended at its 5' end by 51 or fewer nucleotides occurring in the sequence encoding a nonstructural protein (e.g., alphavirus NSP4). In one embodiment, the extended SG promoter is encoded by a sequence comprising or consisting of the sequence set forth in SEQ ID NO: 1, extended at its 5' end by 51 or fewer nucleotides occurring in the sequence encoding a nonstructural protein (e.g., alphavirus NSP4). For example, the extended SG promoter is 100 or fewer nucleotides in length. In one embodiment, the extended SG promoter is encoded by a sequence comprising or consisting of nucleotides 2 to 101 of SEQ ID NO:15.
[0162] In one example, the SG promoter is extended at its 5' end by about 5 to about 20 nucleotides occurring in the sequence encoding a nonstructural protein (e.g., alphavirus NSP4), e.g., by about 5 nucleotides, or about 10 nucleotides, or about 12 nucleotides, or about 15 nucleotides, or about 20 nucleotides. In another example, the SG promoter is extended at its 5' end by about 20 to about 35 nucleotides occurring in the sequence encoding a nonstructural protein (e.g., alphavirus NSP4), e.g., by about 25 nucleotides, or about 27 nucleotides, or about 30 nucleotides, or about 35 nucleotides.
[0163] In one embodiment, the SG promoter is extended at the 5' end by approximately 12 nucleotides occurring in the sequence encoding a nonstructural protein (e.g., alphavirus NSP4). In one embodiment, the extended SG promoter is encoded by the sequence set forth in SEQ ID NO: 1, extended at the 5' end by 12 nucleotides occurring in the sequence encoding a nonstructural protein (e.g., alphavirus NSP4). For example, the extended SG promoter is 61 nucleotides or less in length. In one embodiment, the extended SG promoter is encoded by a sequence comprising or consisting of nucleotides 41-101 of SEQ ID NO: 15. In another embodiment, the extended SG promoter is encoded by a sequence comprising or consisting of the sequence set forth in SEQ ID NO: 2.
[0164] In one embodiment, the SG promoter is extended at the 5' end by approximately 31 nucleotides occurring in the sequence encoding a nonstructural protein (e.g., alphavirus NSP4). In one embodiment, the extended SG promoter is encoded by the sequence set forth in SEQ ID NO: 1, extended at the 5' end by 31 nucleotides occurring in the sequence encoding a nonstructural protein (e.g., alphavirus NSP4). For example, the extended SG promoter is 80 nucleotides or less in length. In one embodiment, the extended SG promoter is encoded by a sequence comprising or consisting of nucleotides 22-101 of SEQ ID NO: 15. In another embodiment, the extended SG promoter is encoded by a sequence comprising or consisting of the sequence set forth in SEQ ID NO: 3.
[0165] In one example, the extended SG promoter comprises a repeat sequence corresponding to nucleotides 66-75 of SEQ ID NO: 15. For example, the extended SG promoter is encoded by a sequence comprising nucleotides 50-75 of SEQ ID NO: 15 and nucleotides 66-101 of SEQ ID NO: 15. For example, the extended SG promoter is encoded by the sequence set forth in SEQ ID NO: 47.
[0166] In one example, the IRES is a wild-type IRES from encephalomyocarditis virus (EMCV). For example, the wild-type EMCV IRES comprises the sequence set forth in SEQ ID NO:4.
[0167] In one embodiment, the first and / or second nucleotide sequence and / or one or more additional nucleotide sequences are codon optimized.
[0168] In one embodiment, the G / C content of the first and / or second nucleotide sequence and / or one or more additional nucleotide sequences is modified.
[0169] In one example, the G / C content of the first and / or second nucleotide sequence and / or one or more additional nucleotide sequences is increased by at least 5% compared to the G / C content of the unmodified sequence, for example, the G / C content of the first and / or second nucleotide sequence and / or one or more additional nucleotide sequences is increased by at least 10%, or 15%, or 20%, or 25%, or 30%, or 35%, or 40% compared to the G / C content of the unmodified sequence.
[0170] In one embodiment, the polynucleotide comprises at least one chemically modified nucleotide.
[0171] In one embodiment, the chemically modified nucleotide is selected from the group consisting of N6,2'-O-dimethyl-adenosine (m6Am), 5-methyluridine (m5U), N4-acetylcytidine (ac4C), 2-thiocytidine (s2C), 2-thiouridine (s2U), 5-methylcytidine (m5C), N6-methyladenosine (m6a), pseudouridine (ψ), 1-methylpseudouridine (m1ψ), and combinations thereof. For example, the chemically modified nucleotide is N6,2'-O-dimethyl-adenosine (m6Am). For example, the chemically modified nucleotide is 5-methyluridine (m5U). For example, the chemically modified nucleotide is N4-acetylcytidine (ac4C). For example, the chemically modified nucleotide is 2-thiocytidine (s2C). For example, the chemically modified nucleotide is 2-thiouridine (s2U). For example, the chemically modified nucleotide is 5-methylcytidine (m5C). For example, the chemically modified nucleotide is N6-methyladenosine (m6a). For example, the chemically modified nucleotide is pseudouridine (ψ). For example, the chemically modified nucleotide is 1-methylpseudouridine (m1ψ).
[0172] In one embodiment, the first nucleotide sequence comprises the 5'-UTR of haptoglobin (HP), fibrinogen beta chain (FGB), haptoglobin-related protein (HPR), albumin (ALB), complement component 3 (C3), fibrinogen alpha chain (FGA), alpha 6 collagen (Col6A), alpha-1-antitrypsin (SERPINA1), alpha-1-antichymotrypsin (SERPINA3), or fragments and / or variants thereof.
[0173] In one example, the 5'UTR is the 5'UTR of Venezuelan Equine Encephalitis Virus (VEEV) or a modified form thereof. For example, the 5'UTR comprises the sequence set forth in SEQ ID NO:45.
[0174] In one embodiment, the 5'-UTR, fragment, and / or variant thereof is 40 to 2000 nucleotides in length. For example, the 5'-UTR, fragment, and / or variant thereof is 40 to 100 nucleotides in length. For example, the 5'-UTR, fragment, and / or variant thereof is 100 to 250 nucleotides in length. For example, the 5'-UTR, fragment, and / or variant thereof is 250 to 500 nucleotides in length. For example, the 5'-UTR, fragment, and / or variant thereof is 500 to 750 nucleotides in length. For example, the 5'-UTR, fragment, and / or variant thereof is 750 to 1000 nucleotides in length. For example, the 5'-UTR, fragment, and / or variant thereof is 1000 to 1250 nucleotides in length. For example, the 5'-UTR, fragment, and / or variant thereof is 1250 to 1500 nucleotides in length. For example, the 5'-UTR, fragments and / or variants thereof are 1500 to 1750 nucleotides in length. For example, the 5'-UTR, fragments and / or variants thereof are 1750 to 2000 nucleotides in length.
[0175] In one example, the 5'-UTR, fragments and / or variants thereof comprise a nucleotide sequence that is at least 90% identical to the nucleotide sequence set forth in any one of SEQ ID NOs: 40-54. For example, the 5'-UTR, fragments and / or variants thereof comprise a nucleotide sequence that is 90%, or 91%, or 92%, or 93%, or 94%, or 95%, or 96%, or 97%, or 98%, or 99% identical to the nucleotide sequence set forth in any one of SEQ ID NOs: 40-54.
[0176] In one embodiment, the polynucleotide comprises a combination of two or more 5'-UTRs, fragments and / or variants thereof. In one embodiment, two or more 5'-UTRs are the same. In one embodiment, two or more 5'-UTRs are different.
[0177] In one embodiment, the nucleotide sequence comprising the 5'UTR comprises at least one microRNA binding site, an AU-rich element (ARE), a GC-rich element, a stem-loop, or a combination thereof. In one embodiment, the nucleotide sequence comprises a microRNA binding site. In one embodiment, the nucleotide sequence comprises an AU-rich element (ARE). In one embodiment, the nucleotide comprises a GC-rich element. In one embodiment, the nucleotide sequence comprises a stem-loop. For example, the stem-loop is a histone stem-loop.
[0178] In one embodiment, the polynucleotide further comprises a nucleotide sequence comprising a 3' UTR. In one embodiment, the nucleotide sequence comprising the 3' UTR is located 3' of a second or one or more additional nucleotide sequences. For example, the nucleotide sequence comprising the 3' UTR is located 3' of a second nucleotide sequence. In one embodiment, the 3' UTR comprises the 3'-UTR of arachidonate 5-lipoxygenase (ALOX5), alpha I collagen (COL1A1), tyrosine hydroxylase (TH) gene, amino-terminal enhancer of split (AES), human mitochondrial 12S rRNA (mtRNR1), fragments and / or variants thereof.
[0179] In one example, the 3'UTR is the 3'UTR of Sindbis virus (SINV) or a modified form thereof, for example, the 3'UTR comprises the sequence set forth in SEQ ID NO:46.
[0180] In one embodiment, the 3'-UTR, its fragment, and / or variant is 40 to 400 nucleotides in length. For example, the 3'-UTR is 40 to 50, 50 to 60, 60 to 70, 70 to 80, 80 to 90, 90 to 100, 100 to 125, 125 to 150, 150 to 175, 175 to 200, 200 to 225, 225 to 250, 250 to 275, 275 to 300, 300 to 325, 325 to 350, 350 to 375, or 375 to 400 nucleotides in length. For example, the 3'-UTR, its fragment, and / or variant is 40 to 50 nucleotides in length. For example, the 3'-UTR, its fragment, and / or variant is 50 to 60 nucleotides in length. For example, the 3'-UTR, fragments, and / or variants thereof are 60 to 70 nucleotides in length. For example, the 3'-UTR, fragments, and / or variants thereof are 70 to 80 nucleotides in length. For example, the 3'-UTR, fragments, and / or variants thereof are 80 to 90 nucleotides in length. For example, the 3'-UTR, fragments, and / or variants thereof are 90 to 100 nucleotides in length. For example, the 3'-UTR, fragments, and / or variants thereof are 100 to 125 nucleotides in length. For example, the 3'-UTR, fragments, and / or variants thereof are 125 to 150 nucleotides in length. For example, the 3'-UTR, fragments, and / or variants thereof are 150 to 175 nucleotides in length. For example, the 3'-UTR, fragments, and / or variants thereof are 175 to 200 nucleotides in length. For example, the 3'-UTR, fragments, and / or variants thereof are 200 to 225 nucleotides in length. For example, the 3'-UTR, fragments and / or variants thereof are 225 to 250 nucleotides in length. For example, the 3'-UTR, fragments and / or variants thereof are 250 to 275 nucleotides in length. For example, the 3'-UTR, fragments and / or variants thereof are 275 to 300 nucleotides in length. For example, the 3'-UTR, fragments and / or variants thereof are 300 to 325 nucleotides in length. For example, the 3'-UTR, fragments and / or variants thereof are 325 to 350 nucleotides in length. For example, the 3'-UTR, fragments and / or variants thereof are 350 to 375 nucleotides in length.For example, the 3'-UTR, fragments and / or variants thereof are 375 to 400 nucleotides in length.
[0181] In one embodiment, the polynucleotide comprises a combination of two or more 3'-UTRs, fragments and / or variants thereof. In one embodiment, two or more 3'-UTRs are the same. In one embodiment, two or more 3'-UTRs are different.
[0182] In one embodiment, the nucleotide sequence comprising the 3' UTR, fragment, and / or variant thereof comprises at least one microRNA binding site, an AU-rich element (ARE), a GC-rich element, a triple helix, a stem-loop, one or more stop codons, and combinations thereof. In one embodiment, the nucleotide sequence comprises a microRNA binding site. In one embodiment, the nucleotide sequence comprises an AU-rich element (ARE). In one embodiment, the nucleotide sequence comprises a GC-rich element. In one embodiment, the nucleotide sequence comprises a triple helix. In one embodiment, the nucleotide sequence comprises a stem-loop. For example, the stem-loop is a histone stem-loop. In one embodiment, the nucleotide sequence comprises one or more stop codons. For example, the one or more stop codons are located at the 5' end of the 3' UTR.
[0183] In one embodiment, the polynucleotide comprises a nucleotide sequence comprising one or more 3' tailing sequences located at the 3' end of the nucleotide sequence comprising the 3' UTR. In one embodiment, the one or more 3' tailing sequences are selected from the group consisting of a polyA sequence, a polyadenylation signal, a G-quadruplex, a polyC sequence, a stem-loop, and combinations thereof. For example, the 3' tailing sequence comprises a polyA sequence. In one embodiment, the 3' tailing sequence comprises a polyadenylation signal. In one embodiment, the 3' tailing sequence comprises a G-quadruplex. In one embodiment, the 3' tailing sequence comprises a poly-C sequence. In one embodiment, the 3' tailing sequence comprises a stem-loop. For example, the stem-loop is a histone stem-loop. In one embodiment, the 3' tailing sequence comprises a polyA sequence and a G-quadruplex. In one embodiment, the 3' tailing sequence comprises a stem-loop (e.g., a histone stem-loop) and a polyA sequence.
[0184] In one embodiment, the one or more 3' tailing sequences comprise one or more polyA sequences, each comprising 10 to 300 consecutive adenosine nucleotides. For example, the polyA sequences each comprise 10 to 20, 20 to 30, 30 to 40, 40 to 50, 50 to 60, 60 to 70, 70 to 80, 80 to 90, 90 to 100, 100 to 125, 125 to 150, 150 to 175, 175 to 200, 200 to 225, 225 to 250, 250 to 275, or 275 to 300 consecutive adenosine nucleotides. For example, the one or more polyA sequences each comprise 10 to 20 consecutive adenosine nucleotides. For example, the one or more polyA sequences each comprise 20 to 30 consecutive adenosine nucleotides. For example, one or more polyA sequences each contain 30 to 40 consecutive adenosine nucleotides. For example, one or more polyA sequences each contain 36 consecutive adenosine nucleotides. For example, one or more polyA sequences each contain 40 to 50 consecutive adenosine nucleotides. For example, one or more polyA sequences each contain 50 to 60 consecutive adenosine nucleotides. For example, one or more polyA sequences each contain 60 to 70 consecutive adenosine nucleotides. For example, one or more polyA sequences each contain 70 to 80 consecutive adenosine nucleotides. For example, one or more polyA sequences each contain 80 to 90 consecutive adenosine nucleotides. For example, one or more polyA sequences each contain 90 to 100 consecutive adenosine nucleotides. For example, one or more polyA sequences each contain 100 to 125 consecutive adenosine nucleotides. For example, each of the one or more polyA sequences contains 125 to 150 consecutive adenosine nucleotides. For example, each of the one or more polyA sequences contains 150 to 175 consecutive adenosine nucleotides. For example, each of the one or more polyA sequences contains 175 to 200 consecutive adenosine nucleotides. For example, each of the one or more polyA sequences contains 200 to 225 consecutive adenosine nucleotides. For example, each of the one or more polyA sequences contains 225 to 250 consecutive adenosine nucleotides.For example, the one or more polyA sequences each contain 250 to 275 consecutive adenosine nucleotides, For example, the one or more polyA sequences each contain 275 to 300 consecutive adenosine nucleotides.
[0185] In one example, the one or more polyA sequences each contain 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, or 300 consecutive adenosine nucleotides. For example, the one or more polyA sequences each contain 10 consecutive adenosine nucleotides. For example, the one or more polyA sequences each contain 20 consecutive adenosine nucleotides. For example, the one or more polyA sequences each contain 30 consecutive adenosine nucleotides. For example, the one or more polyA sequences each contain 40 consecutive adenosine nucleotides. For example, the one or more polyA sequences each contain 50 consecutive adenosine nucleotides. For example, one or more polyA sequences each contain 60 consecutive adenosine nucleotides. For example, one or more polyA sequences each contain 70 consecutive adenosine nucleotides. For example, one or more polyA sequences each contain 80 consecutive adenosine nucleotides. For example, one or more polyA sequences each contain 90 consecutive adenosine nucleotides. For example, one or more polyA sequences each contain 100 consecutive adenosine nucleotides. For example, one or more polyA sequences each contain 125 consecutive adenosine nucleotides. For example, one or more polyA sequences each contain 150 consecutive adenosine nucleotides. For example, one or more polyA sequences each contain 175 consecutive adenosine nucleotides. For example, one or more polyA sequences each contain 200 consecutive adenosine nucleotides. For example, one or more polyA sequences each contain 225 consecutive adenosine nucleotides. For example, one or more polyA sequences each contain 250 consecutive adenosine nucleotides. For example, one or more polyA sequences each contain 275 consecutive adenosine nucleotides. For example, one or more polyA sequences each contain 300 consecutive adenosine nucleotides.
[0186] In one example, the polyA sequence comprises 36 consecutive adenosine nucleotides, for example, the polyA sequence comprises the sequence set forth in SEQ ID NO:48.
[0187] In one embodiment, one or more polyA sequences are separated by an interrupted linker, e.g., the 3' tailing sequence comprises, in 5' to 3' order, a polyA sequence comprising consecutive adenosine nucleotides, an interrupted linker, and another polyA sequence comprising consecutive adenosine nucleotides.
[0188] In one embodiment, the interruption linker is 10 to 50, or 50 to 100, or 100 to 150 nucleotides in length. For example, the interruption linker is 10 to 50 nucleotides in length. For example, the interruption linker is 50 to 100 nucleotides in length. For example, the interruption linker is 100 to 150 nucleotides in length.
[0189] In one example, the interruption linker is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, or 150 nucleotides in length. For example, the interruption linker is 1 nucleotide in length. For example, the interruption linker is 2 nucleotides in length. For example, the interruption linker is 3 nucleotides long. For example, the interruption linker is 4 nucleotides long. For example, the interruption linker is 5 nucleotides long. For example, the interruption linker is 6 nucleotides long. For example, the interruption linker is 7 nucleotides long. For example, the interruption linker is 8 nucleotides long. For example, the interruption linker is 9 nucleotides long. For example, the interruption linker is 10 nucleotides long. For example, the interruption linker is 11 nucleotides long. For example, the interruption linker is 12 nucleotides long. For example, the interruption linker is 13 nucleotides long. For example, the interruption linker is 14 nucleotides long. For example, the interruption linker is 15 nucleotides long. For example, the interruption linker is 16 nucleotides long. For example, the interruption linker is 17 nucleotides long. For example, the interruption linker is 18 nucleotides long. For example, the interruption linker is 19 nucleotides long. For example, the interruption linker is 20 nucleotides long. For example, the interruption linker is 25 nucleotides in length. For example, the interruption linker is 30 nucleotides in length. For example, the interruption linker is 35 nucleotides in length. For example, the interruption linker is 40 nucleotides in length. For example, the interruption linker is 45 nucleotides in length. For example, the interruption linker is 50 nucleotides in length. For example, the interruption linker is 55 nucleotides in length.For example, the interruption linker is 60 nucleotides in length. For example, the interruption linker is 65 nucleotides in length. For example, the interruption linker is 70 nucleotides in length. For example, the interruption linker is 75 nucleotides in length. For example, the interruption linker is 80 nucleotides in length. For example, the interruption linker is 85 nucleotides in length. For example, the interruption linker is 90 nucleotides in length. For example, the interruption linker is 95 nucleotides in length. For example, the interruption linker is 100 nucleotides in length. For example, the interruption linker is 110 nucleotides in length. For example, the interruption linker is 120 nucleotides in length. For example, the interruption linker is 130 nucleotides in length. For example, the interruption linker is 140 nucleotides in length. For example, the interruption linker is 150 nucleotides in length.
[0190] In one embodiment, the interrupted linker is 10 nucleotides in length. In one embodiment, the interrupted linker comprises or consists of the nucleotide sequence set forth in SEQ ID NO: 40. For example, the interrupted linker comprises or consists of the nucleotide sequence GCAUAUGACU.
[0191] In one embodiment, the 3' tailing sequence comprises, from 5' to 3', a polyA sequence comprising 30 consecutive adenosine nucleotides, an interrupted linker of 10 nucleotides, and a further polyA sequence comprising 70 consecutive adenosine nucleotides.
[0192] In one embodiment, the 3' tailing sequence comprises, in 5' to 3' order, a polyA sequence comprising 30 consecutive adenosine nucleotides, an interrupted linker comprising or consisting of the nucleotide sequence set forth in SEQ ID NO: 40, and a further polyA sequence comprising 70 consecutive adenosine nucleotides.
[0193] In one embodiment, the polynucleotide comprises, in 5' to 3' order: a) 5'-UTR, fragments and / or variants thereof; b) a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; c) a first nucleotide sequence encoding a first polypeptide of interest; d) a second nucleotide sequence encoding a second polypeptide of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; e) 3'-UTR, fragments and / or variants thereof, and f) comprising one or more 3' tailing sequences selected from the group consisting of a polyA sequence, a polyadenylation signal, a G-quadruplex, a polyC sequence, a stem-loop, and combinations thereof.
[0194] In one embodiment, the RNA comprises, in 5' to 3' order: a) 5'-UTR, fragments and / or variants thereof; b) a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; c) a first nucleotide sequence encoding a first polypeptide of interest; d) a second nucleotide sequence encoding a second polypeptide of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; e) 3'-UTR, fragments and / or variants thereof, and f) comprising one or more 3' tailing sequences selected from the group consisting of a polyA sequence, a polyadenylation signal, a G-quadruplex, a polyC sequence, a stem-loop, and combinations thereof.
[0195] In one embodiment, the cRNA comprises, in 5' to 3' order: a) 5'-UTR, fragments and / or variants thereof; b) a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; c) a first nucleotide sequence encoding a first polypeptide of interest; d) a second nucleotide sequence encoding a second polypeptide of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; e) 3'-UTR, fragments and / or variants thereof, and f) comprising one or more 3' tailing sequences selected from the group consisting of a polyA sequence, a polyadenylation signal, a G-quadruplex, a polyC sequence, a stem-loop, and combinations thereof.
[0196] In one embodiment, the sa-mRNA comprises, in 5' to 3' order: a) 5'-UTR, fragments and / or variants thereof; b) a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; c) a first nucleotide sequence encoding a first polypeptide of interest; d) a second nucleotide sequence encoding a second polypeptide of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; e) 3'-UTR, fragments and / or variants thereof, and f) comprising one or more 3' tailing sequences selected from the group consisting of a polyA sequence, a polyadenylation signal, a G-quadruplex, a polyC sequence, a stem-loop, and combinations thereof.
[0197] In one example, the multicistronic self-replicating RNA of the present disclosure comprises, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen operably linked to a minimal SG promoter, and a second nucleotide sequence encoding a second antigen operably linked to a minimal SG promoter; or b) a first nucleotide sequence encoding a first antigen operably linked to a minimal SG promoter and a second nucleotide sequence encoding a second antigen operably linked to an extended SG promoter; or c) A first nucleotide sequence encoding a first antigen operably linked to a minimal SG promoter, and a second nucleotide sequence encoding a second antigen operably linked to a wild-type EMCV IRES.
[0198] In one example, a multicistronic self-replicating RNA of the present disclosure comprises, in 5' to 3' order, a first nucleotide sequence encoding a first antigen operably linked to a minimal SG promoter, and a second nucleotide sequence encoding a second antigen operably linked to a minimal SG promoter.
[0199] For example, a multicistronic self-replicating RNA of the present disclosure comprises, in 5' to 3' order, a first nucleotide sequence encoding a first antigen operably linked to a minimal SG promoter comprising the sequence set forth in SEQ ID NO:1, and a second nucleotide sequence encoding a second antigen operably linked to a minimal SG promoter comprising the sequence set forth in SEQ ID NO:1.
[0200] In one example, a multicistronic self-replicating RNA of the present disclosure comprises, in 5' to 3' order, a first nucleotide sequence encoding a first antigen operably linked to a minimal SG promoter, and a second nucleotide sequence encoding a second antigen operably linked to an extended SG promoter.
[0201] In one example, a multicistronic self-replicating RNA of the present disclosure comprises, in 5' to 3' order, a first nucleotide sequence encoding a first antigen operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1, and a second nucleotide sequence encoding a second antigen operably linked to an extended SG promoter encoded by the sequence set forth in SEQ ID NO:2.
[0202] In one example, a multicistronic self-replicating RNA of the present disclosure comprises, in 5' to 3' order, a first nucleotide sequence encoding a first antigen operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1, and a second nucleotide sequence encoding a second antigen operably linked to an extended SG promoter encoded by the sequence set forth in SEQ ID NO:3.
[0203] In one example, a multicistronic self-replicating RNA of the present disclosure comprises, in 5' to 3' order, a first nucleotide sequence encoding a first antigen operably linked to a minimal SG promoter, and a second nucleotide sequence encoding a second antigen operably linked to a wild-type EMCV IRES.
[0204] In one example, a multicistronic self-replicating RNA of the present disclosure comprises, in 5' to 3' order, a first nucleotide sequence encoding a first antigen operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1, and a second nucleotide sequence encoding a second antigen operably linked to a wild-type EMCV IRES encoded by the sequence set forth in SEQ ID NO:4.
[0205] In one embodiment, the RNA further comprises a 5'-end cap structure.
[0206] In one embodiment, the 5'-terminal cap structure is an endogenous cap or an analog thereof. For example, the 5'-terminal cap structure is an endogenous cap. For example, the 5'-terminal cap structure is an analog of an endogenous cap.
[0207] In one embodiment, the 5'-terminal cap structure comprises guanine or a guanine analog thereof. For example, the 5'-terminal cap structure comprises guanine. For example, the 5'-terminal cap structure comprises a guanine analog of guanine.
[0208] In one embodiment, the 5'-terminal cap structure is selected from the group consisting of anti-reverse cap analog (ARCA), N7,2'-O-dimethyl-guanosine (mCAP), inosine, N1-methyl-guanosine, 2'fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, 2-azido-guanosine, N6,2'-O-dimethyladenosine, 7-methylguanosine (m7G), Cap 1, and Cap 2. For example, the 5'-terminal cap structure is anti-reverse cap analog (ARCA). For example, the 5'-terminal cap structure is N7,2'-O-dimethyl-guanosine (mCAP). For example, the 5'-terminal cap structure is inosine. For example, the 5'-terminal cap structure is N1-methyl-guanosine. For example, the 5'-terminal cap structure is 2'fluoro-guanosine. For example, the 5'-end cap structure is 7-deaza-guanosine. For example, the 5'-end cap structure is 8-oxo-guanosine. For example, the 5'-end cap structure is 2-amino-guanosine. For example, the 5'-end cap structure is LNA-guanosine. For example, the 5'-end cap structure is 2-azido-guanosine. For example, the 5'-end cap structure is N6,2'-O-dimethyladenosine. For example, the 5'-end cap structure is 7-methylguanosine (m7G). For example, the 5'-end cap structure is Cap1. For example, the 5'-end cap structure is Cap2.
[0209] In one example, the 5'-terminal cap structure is linked to the 5'-terminus of the RNA by a 5'-5'-triphosphate linkage or a 5'-5' phosphorothioate linkage. For example, the 5'-terminal cap structure is linked to the 5'-terminus of the RNA by a 5'-5'-triphosphate linkage. For example, the 5'-terminal cap structure is linked to the 5'-terminus of the RNA by a 5'-5' phosphorothioate linkage.
[0210] In one example, the antigens are expressed at substantially the same level. For example, the antigens have levels of expression within about 10%, or about 5%, or about 1% of each other. In another example, the antigens are expressed at different levels. For example, the antigens have levels of expression that are greater than about 10%, or about 15%, or about 20% of each other. Methods for determining levels of expression are known in the art and / or described herein.
[0211] In one embodiment, the self-replicating RNA is derived from an alphavirus, for example, an alphavirus selected from the group consisting of Semliki Forest virus (SFV), Sindbis virus (SIN), and Venezuelan equine encephalitis virus (VEE), and combinations thereof.
[0212] In one embodiment, the self-replicating RNA is derived from Semliki Forest Virus (SFV).
[0213] In one embodiment, the self-replicating RNA is derived from Sindbis virus (SIN).
[0214] In one example, the self-replicating RNA is derived from Venezuelan equine encephalitis virus (VEE).
[0215] In one embodiment, the antigen is a viral antigen, for example, the viral antigen is derived from a respiratory virus, in one embodiment, the respiratory virus is selected from the group consisting of influenza virus, respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, coronavirus, adenovirus, and bocavirus.
[0216] In one embodiment, the viral antigen is derived from an influenza virus.
[0217] In one embodiment, the viral antigen is derived from respiratory syncytial virus.
[0218] In one embodiment, the viral antigen is derived from a parainfluenza virus.
[0219] In one embodiment, the viral antigen is derived from a Metapneumovirus.
[0220] In one embodiment, the viral antigen is derived from a rhinovirus.
[0221] In one embodiment, the viral antigen is derived from a coronavirus.
[0222] In one embodiment, the viral antigen is derived from an adenovirus.
[0223] In one embodiment, the viral antigen is derived from bocavirus.
[0224] In one embodiment, the antigen is a viral antigen derived from an influenza virus or a coronavirus.
[0225] In one example, the antigens are from a single strain of influenza virus (i.e., monovalent) or from multiple strains (i.e., multivalent). For example, the self-replicating RNA includes antigens from one or more (e.g., one, two, or three) influenza virus strains.
[0226] In one example, the first and second influenza virus antigens are from different strains of influenza virus, for example, the first and second antigens are from influenza A, B and / or C virus strains.
[0227] In one example, the antigen is derived from an influenza A virus strain. For example, the antigen is an influenza A virus hemagglutinin (HA) protein, neuraminidase (NA) protein, matrix (M) protein, nucleoprotein (NP), nonstructural (NS) protein, or an immunogenic fragment or variant thereof. In one example, the antigen is an influenza A hemagglutinin (HA) subtype H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, or H16, and / or an influenza A neuraminidase (NA) subtype N1, N2, N3, N4, N5, N6, N7, N8, or N9, and / or an influenza A matrix (M) protein subtype M1 or M2, and / or an influenza A nonstructural (NS) protein subtype NS1 or NS2.
[0228] In one example, the influenza virus antigens are from different subtypes of influenza virus, for example, different hemagglutinin subtypes, and / or different neuraminidase subtypes, and / or matrix protein subtypes, and / or nucleoprotein subtypes, and / or nonstructural protein subtypes.
[0229] Those skilled in the art will recognize that pandemic strains of influenza virus are generally H1, H2, H3, H5, H6, H7, or H9 subtype influenza A virus strains, e.g., H1N1, H2N2, H3N2, H5N1, H5N3, H6N1, H7N2, H7N3, H7N7, H7N9, and H9N2 strains.
[0230] In one embodiment, the antigens are from influenza A virus strains with the same hemagglutinin subtype. In another embodiment, the antigens are from influenza A virus strains with different hemagglutinin subtypes. In one embodiment, the antigen is an H1, H2, H3, H5, H6, H7, or H9 subtype influenza A virus strain. For example, the antigen is an H1 hemagglutinin, or an H2 hemagglutinin, or an H3 hemagglutinin, or an H5 hemagglutinin, or an H6 hemagglutinin, or an H7 hemagglutinin, or an H9 hemagglutinin. For example, the antigen is an H5 subtype influenza A virus strain (i.e., an H5 hemagglutinin). In one embodiment, the H5 hemagglutinin is from the A / turkey / Turkey / 1 / 2005 virus strain. For example, the H5 hemagglutinin is encoded by the sequence set forth in SEQ ID NO:5. In one example, the H3 hemagglutinin is the A / Delaware / 39 / 2019 virus strain, for example, the H3 hemagglutinin is encoded by the sequence set forth in SEQ ID NO:54.
[0231] In one embodiment, the antigens are influenza A virus strains with the same neuraminidase subtype. In another embodiment, the antigens are influenza A virus strains with different neuraminidase subtypes. In one embodiment, the antigen is an N1, N2, N3, N7, or N9 subtype influenza A virus strain. For example, the antigen is N1 neuraminidase, or N2 neuraminidase, or N3 neuraminidase, or N7 neuraminidase, or N9 neuraminidase. For example, the antigen is an N1 neuraminidase subtype influenza A virus strain. In one embodiment, the N1 neuraminidase is from the A / Turkey / Turkey / 1 / 2005 strain. For example, the N1 neuraminidase is encoded by the sequence set forth in SEQ ID NO: 6. In one embodiment, the N2 neuraminidase is from the A / Delaware / 39 / 2019 virus strain. For example, N2 neuraminidase is encoded by the sequence set forth in SEQ ID NO: 55.
[0232] In one example, the antigens are H5 hemagglutinin protein and / or N1 neuraminidase protein. For example, the first antigen is an H5 hemagglutinin subtype influenza A virus strain and the second antigen is an N1 neuraminidase subtype influenza A virus strain. In one example, the first antigen is an H5 hemagglutinin subtype influenza A virus strain encoded by the sequence set forth in SEQ ID NO:5 and the second antigen is an N1 neuraminidase subtype influenza A virus strain encoded by the sequence set forth in SEQ ID NO:6.
[0233] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an H5 hemagglutinin protein and a second nucleotide sequence encoding an N1 neuraminidase protein; or b) comprises a first nucleotide sequence encoding an N1 neuraminidase protein and a second nucleotide sequence encoding an H5 hemagglutinin protein.
[0234] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein and a second nucleotide sequence encoding an N1 neuraminidase protein.
[0235] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order: a first nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and a second nucleotide sequence encoding an N1 neuraminidase protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0236] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order, a first nucleotide sequence encoding an N1 neuraminidase protein and a second nucleotide sequence encoding an H5 hemagglutinin protein.
[0237] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order: a first nucleotide sequence encoding an N1 neuraminidase protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and a second nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0238] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an H5 hemagglutinin protein and a second nucleotide sequence encoding an N1 neuraminidase protein; or b) comprises a first nucleotide sequence encoding an N1 neuraminidase protein and a second nucleotide sequence encoding an H5 hemagglutinin protein.
[0239] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein and a second nucleotide sequence encoding an N1 neuraminidase protein.
[0240] In one example, the disclosure provides an RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof, and a second nucleotide sequence encoding an N1 neuraminidase protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0241] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an N1 neuraminidase protein and a second nucleotide sequence encoding an H5 hemagglutinin protein.
[0242] In one example, the disclosure provides an RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an N1 neuraminidase protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof, and a second nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0243] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an H5 hemagglutinin protein and a second nucleotide sequence encoding an N1 neuraminidase protein; or b) comprises a first nucleotide sequence encoding an N1 neuraminidase protein and a second nucleotide sequence encoding an H5 hemagglutinin protein.
[0244] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein and a second nucleotide sequence encoding an N1 neuraminidase protein.
[0245] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof, and a second nucleotide sequence encoding an N1 neuraminidase protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0246] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an N1 neuraminidase protein and a second nucleotide sequence encoding an H5 hemagglutinin protein.
[0247] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an N1 neuraminidase protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof, and a second nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0248] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an H5 hemagglutinin protein and a second nucleotide sequence encoding an N1 neuraminidase protein; or b) comprises a first nucleotide sequence encoding an N1 neuraminidase protein and a second nucleotide sequence encoding an H5 hemagglutinin protein.
[0249] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein and a second nucleotide sequence encoding an N1 neuraminidase protein.
[0250] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein operably linked to an SG promoter, and a second nucleotide sequence encoding an N1 neuraminidase protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0251] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and b) a second nucleotide sequence encoding an N1 neuraminidase protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1.
[0252] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and b) a second nucleotide sequence encoding an N1 neuraminidase protein operably linked to an extended SG promoter encoded by the sequence set forth in SEQ ID NO:2.
[0253] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and b) a second nucleotide sequence encoding an N1 neuraminidase protein operably linked to an extended SG promoter encoded by the sequence set forth in SEQ ID NO:3.
[0254] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and b) a second nucleotide sequence encoding an N1 neuraminidase protein operably linked to an IRES encoded by the sequence set forth in SEQ ID NO:4.
[0255] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an N1 neuraminidase protein and a second nucleotide sequence encoding an H5 hemagglutinin protein.
[0256] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an N1 neuraminidase protein operably linked to an SG promoter, and a second nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0257] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an N1 neuraminidase protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and b) a second nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1.
[0258] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an N1 neuraminidase protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and b) a second nucleotide sequence encoding an H5 hemagglutinin protein operably linked to an extended SG promoter encoded by the sequence set forth in SEQ ID NO:2.
[0259] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an N1 neuraminidase protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and b) a second nucleotide sequence encoding an H5 hemagglutinin protein operably linked to an extended SG promoter encoded by the sequence set forth in SEQ ID NO:3.
[0260] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an N1 neuraminidase operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and b) a second nucleotide sequence encoding an H5 hemagglutinin protein operably linked to an IRES encoded by the sequence set forth in SEQ ID NO:4.
[0261] In one example, the antigen is an influenza A virus hemagglutinin (HA) protein and matrix (M) protein. For example, the antigen is an H5 hemagglutinin protein and / or an M1 matrix protein. In one example, the M1 neuraminidase is from the A / Puerto Rico / 8 / 1934 (PR8-X) strain. In another example, the M1 neuraminidase is from the A / California / 07 / 09 strain. In one example, the antigen is an H5 hemagglutinin subtype influenza A virus strain encoded by the sequence set forth in SEQ ID NO:5 and an M1 matrix protein subtype influenza A virus strain encoded by the sequence set forth in SEQ ID NO:16 or SEQ ID NO:29.
[0262] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an H5 hemagglutinin protein and a second nucleotide sequence encoding an M1 matrix protein; or b) comprises a first nucleotide sequence encoding an M1 matrix protein and a second nucleotide sequence encoding an H5 hemagglutinin protein.
[0263] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein and a second nucleotide sequence encoding an M1 matrix protein.
[0264] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof, and a second nucleotide sequence encoding an M1 matrix protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0265] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an H5 hemagglutinin protein and a second nucleotide sequence encoding an M1 matrix protein; or b) comprises a first nucleotide sequence encoding an M1 matrix protein and a second nucleotide sequence encoding an H5 hemagglutinin protein.
[0266] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein and a second nucleotide sequence encoding an M1 matrix protein.
[0267] In one example, the disclosure provides an RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof, and a second nucleotide sequence encoding an M1 matrix protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0268] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an H5 hemagglutinin protein and a second nucleotide sequence encoding an M1 matrix protein; or b) comprises a first nucleotide sequence encoding an M1 matrix protein and a second nucleotide sequence encoding an H5 hemagglutinin protein.
[0269] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein and a second nucleotide sequence encoding an M1 matrix protein.
[0270] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof, and a second nucleotide sequence encoding an M1 matrix protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0271] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an H5 hemagglutinin protein and a second nucleotide sequence encoding an M1 matrix protein; or b) comprises a first nucleotide sequence encoding an M1 matrix protein and a second nucleotide sequence encoding an H5 hemagglutinin protein.
[0272] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein and a second nucleotide sequence encoding an M1 matrix protein.
[0273] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein operably linked to an SG promoter, and a second nucleotide sequence encoding an M1 matrix protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0274] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and b) A second nucleotide sequence encoding an M1 matrix protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1.
[0275] In one example, the antigen is an influenza A virus hemagglutinin (HA) protein, neuraminidase (NA) protein, and matrix (M) protein. For example, the antigen is an H5 hemagglutinin protein, an N1 neuraminidase protein, and / or an M1 matrix protein. In one example, the antigen is an H5 hemagglutinin subtype influenza A virus strain encoded by the sequence set forth in SEQ ID NO:5, an N1 neuraminidase subtype influenza A virus strain encoded by the sequence set forth in SEQ ID NO:6, and an M1 matrix protein subtype influenza A virus strain encoded by the sequence set forth in SEQ ID NO:16 or SEQ ID NO:29.
[0276] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an H5 hemagglutinin protein, a second nucleotide sequence encoding an N1 neuraminidase protein, and a third nucleotide sequence encoding an M1 matrix protein; or b) comprising a first nucleotide sequence encoding an M1 matrix protein, a second nucleotide sequence encoding an N1 neuraminidase protein, and a third nucleotide sequence encoding an H5 hemagglutinin protein.
[0277] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein, a second nucleotide sequence encoding an N1 neuraminidase protein, and a third nucleotide sequence encoding an M1 matrix protein.
[0278] In one example, the disclosure provides a polynucleotide comprising, in 5' to 3' order: a first nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; a second nucleotide sequence encoding an N1 neuraminidase protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and a third nucleotide sequence encoding an M1 matrix protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0279] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order, a first nucleotide sequence encoding an M1 matrix protein, a second nucleotide sequence encoding an N1 neuraminidase protein, and a third nucleotide sequence encoding an H5 hemagglutinin protein.
[0280] In one example, the disclosure provides a polynucleotide comprising, in 5' to 3' order: a first nucleotide sequence encoding an M1 matrix protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; a second nucleotide sequence encoding an N1 neuraminidase protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and a third nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0281] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an H5 hemagglutinin protein, a second nucleotide sequence encoding an N1 neuraminidase protein, and a third nucleotide sequence encoding an M1 matrix protein; or b) comprising a first nucleotide sequence encoding an M1 matrix protein, a second nucleotide sequence encoding an N1 neuraminidase protein, and a third nucleotide sequence encoding an H5 hemagglutinin protein.
[0282] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein, a second nucleotide sequence encoding an N1 neuraminidase protein, and a third nucleotide sequence encoding an M1 matrix protein.
[0283] In one example, the disclosure provides an RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; a second nucleotide sequence encoding an N1 neuraminidase protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and a third nucleotide sequence encoding an M1 matrix protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0284] In one example, the disclosure provides an RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an M1 matrix protein, a second nucleotide sequence encoding an N1 neuraminidase protein, and a third nucleotide sequence encoding an H5 hemagglutinin protein.
[0285] In one example, the disclosure provides an RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an M1 matrix protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; a second nucleotide sequence encoding an N1 neuraminidase protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and a third nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0286] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an H5 hemagglutinin protein, a second nucleotide sequence encoding an N1 neuraminidase protein, and a third nucleotide sequence encoding an M1 matrix protein; or b) comprising a first nucleotide sequence encoding an M1 matrix protein, a second nucleotide sequence encoding an N1 neuraminidase protein, and a third nucleotide sequence encoding an H5 hemagglutinin protein.
[0287] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein, a second nucleotide sequence encoding an N1 neuraminidase protein, and a third nucleotide sequence encoding an M1 matrix protein.
[0288] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order: a first nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; a second nucleotide sequence encoding an N1 neuraminidase protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and a third nucleotide sequence encoding an M1 matrix protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0289] In one example, the disclosure provides a cRNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an M1 matrix protein, a second nucleotide sequence encoding an N1 neuraminidase protein, and a third nucleotide sequence encoding an H5 hemagglutinin protein.
[0290] In one example, the disclosure provides a cRNA, the RNA comprising, in 5' to 3' order: a first nucleotide sequence encoding an M1 matrix protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; a second nucleotide sequence encoding an N1 neuraminidase protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and a third nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0291] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an H5 hemagglutinin protein, a second nucleotide sequence encoding an N1 neuraminidase protein, and a third nucleotide sequence encoding an M1 matrix protein; or b) comprising a first nucleotide sequence encoding an M1 matrix protein, a second nucleotide sequence encoding an N1 neuraminidase protein, and a third nucleotide sequence encoding an H5 hemagglutinin protein.
[0292] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein, a second nucleotide sequence encoding an N1 neuraminidase protein, and a third nucleotide sequence encoding an M1 matrix protein.
[0293] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein operably linked to an SG promoter, a second nucleotide sequence encoding an N1 neuraminidase protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and a third nucleotide sequence encoding an M1 matrix protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0294] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; b) a second nucleotide sequence encoding an N1 neuraminidase protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and c) a third nucleotide sequence encoding an M1 matrix protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1.
[0295] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an M1 matrix protein, a second nucleotide sequence encoding an N1 neuraminidase protein, and a third nucleotide sequence encoding an H5 hemagglutinin protein.
[0296] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an M1 matrix protein operably linked to an SG promoter, a second nucleotide sequence encoding an N1 neuraminidase protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and a third nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0297] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an M1 matrix protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; b) a second nucleotide sequence encoding an N1 neuraminidase protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and c) a third nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1.
[0298] In one example, the antigen is an influenza A virus HA protein, NA protein, and M protein. For example, the antigen is an H5 hemagglutinin protein, an N1 neuraminidase protein, an M1 matrix protein, and / or an M2 matrix protein. In one example, the antigen is an H5 hemagglutinin subtype influenza A virus strain encoded by the sequence set forth in SEQ ID NO:5, an N1 neuraminidase subtype influenza A virus strain encoded by the sequence set forth in SEQ ID NO:6, an M1 matrix protein subtype influenza A virus strain encoded by the sequence set forth in SEQ ID NO:16 or SEQ ID NO:29, or an M2 matrix protein subtype influenza A virus strain encoded by the sequence set forth in SEQ ID NO:17.
[0299] In one example, the disclosure provides a polynucleotide comprising, in 5' to 3' order, a first nucleotide sequence encoding an M1 matrix protein, a second nucleotide sequence encoding an M2 matrix protein, a third nucleotide sequence encoding an N1 neuraminidase protein, and a fourth nucleotide sequence encoding an H5 hemagglutinin protein.
[0300] In one example, the disclosure provides a polynucleotide comprising, in 5' to 3' order, a first nucleotide sequence encoding an M1 matrix protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; a second nucleotide sequence encoding an M2 matrix protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; a third nucleotide sequence encoding an N1 neuraminidase protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and a fourth nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0301] In one example, the disclosure provides an RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an M1 matrix protein, a second nucleotide sequence encoding an M2 matrix protein, a third nucleotide sequence encoding an N1 neuraminidase protein, and a fourth nucleotide sequence encoding an H5 hemagglutinin protein.
[0302] In one example, the disclosure provides an RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an M1 matrix protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; a second nucleotide sequence encoding an M2 matrix protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; a third nucleotide sequence encoding an N1 neuraminidase protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and a fourth nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0303] In one example, the disclosure provides a cRNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an M1 matrix protein, a second nucleotide sequence encoding an M2 matrix protein, a third nucleotide sequence encoding an N1 neuraminidase protein, and a fourth nucleotide sequence encoding an H5 hemagglutinin protein.
[0304] In one example, the disclosure provides a cRNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an M1 matrix protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; a second nucleotide sequence encoding an M2 matrix protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; a third nucleotide sequence encoding an N1 neuraminidase protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and a fourth nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0305] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an M1 matrix protein, a second nucleotide sequence encoding an M2 matrix protein, a third nucleotide sequence encoding an N1 neuraminidase protein, and a fourth nucleotide sequence encoding an H5 hemagglutinin protein.
[0306] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an M1 matrix protein operably linked to an SG promoter, a second nucleotide sequence encoding an M2 matrix protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, a third nucleotide sequence encoding an N1 neuraminidase protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and a fourth nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0307] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an M1 matrix protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; b) a second nucleotide sequence encoding the M2 matrix protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1. c) a third nucleotide sequence encoding an N1 neuraminidase protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and d) a fourth nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1.
[0308] In one example, the antigen is an influenza A virus HA protein and NS protein. For example, the antigen is an H5 hemagglutinin protein and / or an NS1 nonstructural protein. In one example, the antigen is an H5 hemagglutinin subtype influenza A virus strain encoded by the sequence set forth in SEQ ID NO:5, and an NS1 nonstructural protein subtype influenza A virus strain encoded by the sequence set forth in SEQ ID NO:18.
[0309] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an H5 hemagglutinin protein and a second nucleotide sequence encoding an NS1 nonstructural protein; or b) comprises a first nucleotide sequence encoding the NS1 nonstructural protein and a second nucleotide sequence encoding the H5 hemagglutinin protein.
[0310] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein and a second nucleotide sequence encoding an NS1 nonstructural protein.
[0311] In one example, the disclosure provides a polynucleotide comprising, in 5' to 3' order: a first nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and a second nucleotide sequence encoding an NS1 nonstructural protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0312] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order, a first nucleotide sequence encoding an NS1 nonstructural protein and a second nucleotide sequence encoding an H5 hemagglutinin protein.
[0313] In one example, the disclosure provides a polynucleotide comprising, in 5' to 3' order: a first nucleotide sequence encoding an NS1 nonstructural protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and a second nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0314] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an H5 hemagglutinin protein and a second nucleotide sequence encoding an NS1 nonstructural protein; or b) comprises a first nucleotide sequence encoding the NS1 nonstructural protein and a second nucleotide sequence encoding the H5 hemagglutinin protein.
[0315] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein and a second nucleotide sequence encoding an NS1 nonstructural protein.
[0316] In one example, the disclosure provides an RNA comprising, in 5' to 3' order: a first nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and a second nucleotide sequence encoding an NS1 nonstructural protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0317] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an NS1 nonstructural protein and a second nucleotide sequence encoding an H5 hemagglutinin protein.
[0318] In one example, the disclosure provides an RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an NS1 nonstructural protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and a second nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0319] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an H5 hemagglutinin protein and a second nucleotide sequence encoding an NS1 nonstructural protein; or b) comprises a first nucleotide sequence encoding the NS1 nonstructural protein and a second nucleotide sequence encoding the H5 hemagglutinin protein.
[0320] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein and a second nucleotide sequence encoding an NS1 nonstructural protein.
[0321] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order: a first nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and a second nucleotide sequence encoding an NS1 nonstructural protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0322] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an NS1 nonstructural protein and a second nucleotide sequence encoding an H5 hemagglutinin protein.
[0323] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order: a first nucleotide sequence encoding an NS1 nonstructural protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and a second nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0324] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an H5 hemagglutinin protein and a second nucleotide sequence encoding an NS1 nonstructural protein; or b) comprises a first nucleotide sequence encoding the NS1 nonstructural protein and a second nucleotide sequence encoding the H5 hemagglutinin protein.
[0325] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein and a second nucleotide sequence encoding an NS1 nonstructural protein.
[0326] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an H5 hemagglutinin protein operably linked to an SG promoter, and a second nucleotide sequence encoding an NS1 nonstructural protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0327] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and b) a second nucleotide sequence encoding the NS1 nonstructural protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1.
[0328] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an NS1 nonstructural protein and a second nucleotide sequence encoding an H5 hemagglutinin protein.
[0329] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an NS1 nonstructural protein operably linked to an SG promoter, a second nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0330] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an NS1 nonstructural protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and b) a second nucleotide sequence encoding an H5 hemagglutinin protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1.
[0331] In one example, the antigen is an influenza A virus M protein and NP. For example, the antigen is an M1 matrix protein and / or an NP protein. In one example, the NP protein is the A / California / 07 / 09 strain. In one example, the antigen is an M1 matrix protein subtype influenza A virus strain encoded by the sequence set forth in SEQ ID NO: 16 or SEQ ID NO: 29, and an NP nucleoprotein encoded by the sequence set forth in SEQ ID NO: 28.
[0332] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an M1 matrix protein and a second nucleotide sequence encoding an NP nucleoprotein; or b) comprises a first nucleotide sequence encoding an NP nucleoprotein and a second nucleotide sequence encoding an M1 matrix protein.
[0333] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order, a first nucleotide sequence encoding an M1 matrix protein and a second nucleotide sequence encoding an NP nucleoprotein.
[0334] In one example, the disclosure provides a polynucleotide comprising, in 5' to 3' order: a first nucleotide sequence encoding an M1 matrix protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and a second nucleotide sequence encoding an NP nucleoprotein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0335] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an M1 matrix protein and a second nucleotide sequence encoding an NP nucleoprotein; or b) comprises a first nucleotide sequence encoding an NP nucleoprotein and a second nucleotide sequence encoding an M1 matrix protein.
[0336] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an M1 matrix protein and a second nucleotide sequence encoding an NP nucleoprotein.
[0337] In one example, the disclosure provides an RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an M1 matrix protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and a second nucleotide sequence encoding an NP nucleoprotein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0338] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an M1 matrix protein and a second nucleotide sequence encoding an NP nucleoprotein; or b) comprises a first nucleotide sequence encoding an NP nucleoprotein and a second nucleotide sequence encoding an M1 matrix protein.
[0339] In one example, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an M1 matrix protein and a second nucleotide sequence encoding an NP nucleoprotein.
[0340] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an M1 matrix protein operably linked to an SG promoter, and a second nucleotide sequence encoding an NP nucleoprotein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0341] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an M1 matrix protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and b) A second nucleotide sequence encoding a NP nucleoprotein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1.
[0342] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an M1 matrix protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and b) A second nucleotide sequence encoding an NP nucleoprotein operably linked to an extended SG promoter encoded by the sequence set forth in SEQ ID NO:2.
[0343] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order: c) a first nucleotide sequence encoding an H3 hemagglutinin protein and a second nucleotide sequence encoding an N2 neuraminidase protein; or d) comprises a first nucleotide sequence encoding an N2 neuraminidase protein and a second nucleotide sequence encoding an H3 hemagglutinin protein.
[0344] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order, a first nucleotide sequence encoding an H3 hemagglutinin protein and a second nucleotide sequence encoding an N2 neuraminidase protein.
[0345] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order: a first nucleotide sequence encoding an H3 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and a second nucleotide sequence encoding an N2 neuraminidase protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0346] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order, a first nucleotide sequence encoding an N2 neuraminidase protein and a second nucleotide sequence encoding an H3 hemagglutinin protein.
[0347] In one example, the disclosure provides a polynucleotide comprising, in 5' to 3' order: a first nucleotide sequence encoding an N2 neuraminidase protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and a second nucleotide sequence encoding an H3 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0348] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order: c) a first nucleotide sequence encoding an H3 hemagglutinin protein and a second nucleotide sequence encoding an N2 neuraminidase protein; or d) comprises a first nucleotide sequence encoding an N2 neuraminidase protein and a second nucleotide sequence encoding an H3 hemagglutinin protein.
[0349] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an H3 hemagglutinin protein and a second nucleotide sequence encoding an N2 neuraminidase protein.
[0350] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order: a first nucleotide sequence encoding an H3 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and a second nucleotide sequence encoding an N2 neuraminidase protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0351] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an N2 neuraminidase protein and a second nucleotide sequence encoding an H3 hemagglutinin protein.
[0352] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order: a first nucleotide sequence encoding an N2 neuraminidase protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and a second nucleotide sequence encoding an H3 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0353] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order: c) a first nucleotide sequence encoding an H3 hemagglutinin protein and a second nucleotide sequence encoding an N2 neuraminidase protein; or d) comprises a first nucleotide sequence encoding an N2 neuraminidase protein and a second nucleotide sequence encoding an H3 hemagglutinin protein.
[0354] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an H3 hemagglutinin protein and a second nucleotide sequence encoding an N2 neuraminidase protein.
[0355] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order: a first nucleotide sequence encoding an H3 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and a second nucleotide sequence encoding an N2 neuraminidase protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0356] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an N2 neuraminidase protein and a second nucleotide sequence encoding an H3 hemagglutinin protein.
[0357] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order: a first nucleotide sequence encoding an N2 neuraminidase protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and a second nucleotide sequence encoding an H3 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0358] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: c) a first nucleotide sequence encoding an H3 hemagglutinin protein and a second nucleotide sequence encoding an N2 neuraminidase protein; or d) comprises a first nucleotide sequence encoding an N2 neuraminidase protein and a second nucleotide sequence encoding an H3 hemagglutinin protein.
[0359] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an H3 hemagglutinin protein and a second nucleotide sequence encoding an N2 neuraminidase protein.
[0360] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an H3 hemagglutinin protein operably linked to an SG promoter, a second nucleotide sequence encoding an N2 neuraminidase protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0361] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: c) a first nucleotide sequence encoding an H3 hemagglutinin protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and d) a second nucleotide sequence encoding an N2 neuraminidase protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1.
[0362] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an N2 neuraminidase protein and a second nucleotide sequence encoding an H3 hemagglutinin protein.
[0363] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a first nucleotide sequence encoding an N2 neuraminidase protein operably linked to an SG promoter; and a second nucleotide sequence encoding an H3 hemagglutinin protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0364] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: c) a first nucleotide sequence encoding an N2 neuraminidase protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and d) a second nucleotide sequence encoding an H3 hemagglutinin protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1.
[0365] In one example, the antigen is an influenza B virus strain. Those skilled in the art will recognize that influenza B viruses are not divided into subtypes, but rather into two lineages: B / Yamagata and B / Victoria.
[0366] In one embodiment, the antigen is the B / Yamagata influenza B virus strain. For example, the influenza B virus strain is the B / Singapore / INFTT 16 0610 / 16 (By) virus strain. In another embodiment, the antigen is the B / Victoria influenza B virus strain. In one embodiment, the antigen is an influenza B virus strain in the same lineage. In another embodiment, the antigen is an influenza B virus strain in a different lineage.
[0367] In one example, the antigen is an influenza B virus Hyam protein and / or Nyam protein. For example, the antigen is an influenza B virus Hyam protein. In another example, the antigen is an influenza B virus Nyam protein. In a further example, the antigen is an influenza B virus Hyam and Nyam protein. In one example, the antigen is a Hyam subtype influenza B virus strain encoded by the sequence set forth in SEQ ID NO: 56 and a Nyam subtype influenza B virus strain encoded by the sequence set forth in SEQ ID NO: 57.
[0368] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order: e) a first nucleotide sequence encoding a Hyam protein and a second nucleotide sequence encoding a Nyam protein; or f) comprising a first nucleotide sequence encoding a Nyam protein and a second nucleotide sequence encoding a Hyam protein.
[0369] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order, a first nucleotide sequence encoding a Hyam protein and a second nucleotide sequence encoding a Nyam protein.
[0370] In one example, the disclosure provides a polynucleotide comprising, in 5' to 3' order: a first nucleotide sequence encoding a Hyam protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and a second nucleotide sequence encoding a Nyam protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0371] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order, a first nucleotide sequence encoding a Nyam protein and a second nucleotide sequence encoding a Hyam protein.
[0372] In one example, the disclosure provides a polynucleotide comprising, in 5' to 3' order: a first nucleotide sequence encoding a Nyam protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and a second nucleotide sequence encoding a Hyam protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0373] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order: e) a first nucleotide sequence encoding a Hyam protein and a second nucleotide sequence encoding a Nyam protein; or f) comprising a first nucleotide sequence encoding a Nyam protein and a second nucleotide sequence encoding a Hyam protein.
[0374] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding a Hyam protein and a second nucleotide sequence encoding a Nyam protein.
[0375] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order: a first nucleotide sequence encoding a Hyam protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and a second nucleotide sequence encoding a Nyam protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0376] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding a Nyam protein and a second nucleotide sequence encoding a Hyam protein.
[0377] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order: a first nucleotide sequence encoding a Nyam protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and a second nucleotide sequence encoding a Hyam protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0378] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order: e) a first nucleotide sequence encoding a Hyam protein and a second nucleotide sequence encoding a Nyam protein; or f) comprising a first nucleotide sequence encoding a Nyam protein and a second nucleotide sequence encoding a Hyam protein.
[0379] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order, a first nucleotide sequence encoding a Hyam protein and a second nucleotide sequence encoding a Nyam protein.
[0380] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order: a first nucleotide sequence encoding a Hyam protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and a second nucleotide sequence encoding a Nyam protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0381] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order, a first nucleotide sequence encoding a Nyam protein and a second nucleotide sequence encoding a Hyam protein.
[0382] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order: a first nucleotide sequence encoding a Nyam protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and a second nucleotide sequence encoding a Hyam protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0383] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: e) a first nucleotide sequence encoding a Hyam protein and a second nucleotide sequence encoding a Nyam protein; or f) comprising a first nucleotide sequence encoding a Nyam protein and a second nucleotide sequence encoding a Hyam protein.
[0384] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding a Hyam protein and a second nucleotide sequence encoding a Nyam protein.
[0385] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a first nucleotide sequence encoding a Hyam protein operably linked to an SG promoter; and a second nucleotide sequence encoding a Nyam protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0386] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: e) a first nucleotide sequence encoding a Hyam protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and f) A second nucleotide sequence encoding a Nyam protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1.
[0387] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding a Nyam protein and a second nucleotide sequence encoding a Hyam protein.
[0388] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding a Nyam protein operably linked to an SG promoter, a second nucleotide sequence encoding a Hyam protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0389] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: e) a first nucleotide sequence encoding a Nyam protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and f) A second nucleotide sequence encoding a Hyam protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1.
[0390] In one embodiment, the antigen is a viral antigen derived from a coronavirus.
[0391] In one example, the antigen is an alphacoronavirus, betacoronavirus, gammacoronavirus, and / or deltacoronavirus strain.
[0392] In one embodiment, the antigen is an alphacoronavirus, for example, the alphacoronavirus is selected from the group consisting of alphacoronavirus 1, human coronavirus 229E (HCoV 229E), human coronavirus NL63 (HCoV NL63), Miniopterus bat coronavirus 1, Miniopterus bat coronavirus HKU8, porcine epidemic diarrhea virus, Rhinolophus bat coronavirus HKU2, and Scotophilus bat coronavirus 512.
[0393] In one embodiment, the antigen is a betacoronavirus. For example, the betacoronavirus is selected from the group consisting of betacoronavirus 1 (bovine coronavirus, human coronavirus OC43), hedgehog coronavirus 1, human coronavirus HKU1 (HCoV HKU1), Middle East respiratory syndrome-related coronavirus (MERS-CoV), murine coronavirus, Pipistrellus bat coronavirus HKU5, Rousettus bat coronavirus HKU9, severe acute respiratory syndrome-related coronavirus (SARS-CoV, SARS-CoV-2), and Tylonycteris bat coronavirus HKU4. In one embodiment, the antigen is derived from a betacoronavirus selected from the group consisting of Middle East respiratory syndrome-related coronavirus (MERS-CoV) and severe acute respiratory syndrome-related coronavirus (SARS-CoV or SARS-CoV-2). For example, the antigen is derived from MERS-CoV. In another embodiment, the antigen is derived from SARS-CoV. In a further embodiment, the antigen is derived from SARS-CoV-2. For example, the coronavirus is SARS-CoV-2.
[0394] In one example, the antigen is a gamma coronavirus, for example, the gamma coronavirus is selected from the group consisting of avian coronavirus and beluga coronavirus SW1.
[0395] In one embodiment, the antigen is a deltacoronavirus, for example, the deltacoronavirus is selected from the group consisting of brown-eared bulbul coronavirus HKU11 and porcine coronavirus HKU15.
[0396] In one embodiment, the antigen is the spike (S) protein and / or the nucleocapsid (N) protein of a coronavirus. For example, the antigen is the SARS-CoV-2 N protein and / or S protein. In one embodiment, the antigen is the SARS-CoV-2 N protein and / or S protein from SARS-CoV-2 strain 2019-nCoV / USA-WA1 / 2020.
[0397] In one example, the antigen is the SARS-CoV-2 N protein. For example, the antigen is the SARS-CoV-2 N protein and is encoded by the sequence set forth in SEQ ID NO:7.
[0398] In another embodiment, the antigen is the SARS-CoV-2 S protein. For example, the antigen is the SARS-CoV-2 spike protein and is encoded by the sequence set forth in SEQ ID NO:8.
[0399] In another embodiment, the S protein is a mutant S protein.
[0400] In one example, the mutant S protein comprises mutations in the receptor binding domain, for example, S438F, N439K, N440K, L441I, K444R, V445A, V445I, G446V, G446S, N450K, L452R, L452P, L455F, K458N, N460T, D467V, I468F, I468T, I468V, E471O, I472V, A475V, G476S, S477G, S477I, S477N, S477R, T478I, In one embodiment, the mutant S protein comprises a mutation in the receptor binding domain selected from the group consisting of N439K, N439L, L452R, S477N, T478I, V483A, and E484D.
[0401] In one example, the mutant S protein comprises mutations in the receptor binding domain, for example, mutations R346K, K417N, K417T, S438F, N439K, N440K, L441I, K444R, V445A, V445I, G446V, G446S, N450K, L452R, L452P, L455F, K458N, N460T, D467V, I468F, I468T, I468V, E471O, I472V, A475V, G476S, S477G, S477I, S477N, S477R, selected from the group consisting of T478I, T478K, P479L, P479S, N481D, N481H, V483F, V483A, E484D, E484K, E484K, E484O, G485S, Y489H, Y489D, Y489F, Y489C, Y489N, F490L, F490S, P491R, Q493L, S494P, Y495N, T500N, N501S, N501Y, Y505H, and Y508H. In one embodiment, the mutant S protein comprises a mutation in the receptor binding domain selected from the group consisting of R346K, K417N, K417T, N439K, N439L, L452R, S477N, T478I, V483A, E484D, E484K, and N501Y.
[0402] In one embodiment, the mutant S protein is selected from the group consisting of P337S, F338L, F338C, G339D, E340K, V341I, A344S, T345S, R346K, A348S, A348T, W353R, N354D, N354K, N354S, S359N, D364Y, V367F, S373L, V382L, P384L, P384S, T385A, T393P, V395I, F400C, R403K, R403S, and a mutation selected from the group consisting of D405V, R408I, Q414E, Q414K, Q414P, Q414R, T415S, K417R, K417N, I418V, Y421S, Y423C, Y423F, Y423S, D427Y, R509K, V510L, V511E, V512L, L518I, H519O, A520S, A520V, P521R, P521S, A522P, A522S, and D614G.
[0403] In one embodiment, the mutant S protein is selected from the group consisting of L18F, D80A, T95I, Y144S, Y145N, D215G, P337S, F338L, F338C, G339D, E340K, V341I, A344S, T345S, R346K, A348S, A348T, W353R, N354D, N354K, N354S, S359N, D364Y, V367F, S373L, V382L, P384L, P384S, T385A, T393P, V395I, F400C, R403K, R403S, D405V, R408I, Q414E, Q414K, Q414P, Q414R, T415S, K417N, K417T, K417R, I418V, Y421S, Y4 23C, Y423F, Y423S, D427Y, S438F, N439K, N440K, L441I, K444R, V445A, V445I, G446V, G446S, N450K, L452R, L452P, L455 F, K458N, N460T, D467V, I468F, I468T, I468V, E471O, I472V, A475V, G476S, S477G, S477I, S477N, S477R, T478I, T478K, P479L, P479S, N481D, N481H, V483F, V483A, E484D, E484K, E484K, E484O, G485S, Y489H, Y489D, Y489F, Y489C, Y489N, F4 and D950N.
[0404] In one embodiment, the mutant S protein (i) lacks a furin cleavage site at the S1 / S2 boundary and contains a RRAR to QQAA mutation at residues corresponding to nucleotides 682-685 of SEQ ID NO: 37, and / or (ii) lacks a furin cleavage site at the S2' site, and / or (iii) contains a D to G mutation at residue corresponding to nucleotide 614 of SEQ ID NO: 37, and / or (iv) contains an insertion of two proline residues between residues corresponding to nucleotides 986 and 987 of SEQ ID NO: 37.
[0405] In one example, the S protein lacks a furin cleavage site at the S1 / S2 boundary and contains an RRAR to QQAA mutation at residues corresponding to nucleotides 682-685 of SEQ ID NO: 37. For example, the mutant S protein is encoded by the sequence set forth in SEQ ID NO: 9.
[0406] In one embodiment, the S protein lacks a furin cleavage site at the S2' site.
[0407] In one example, the S protein includes a D to G mutation at the residue corresponding to nucleotide 614 of SEQ ID NO: 37. For example, the mutant S protein is encoded by the sequence set forth in SEQ ID NO: 36.
[0408] In one example, the S protein includes an insertion of two proline residues between residues corresponding to nucleotides 986 and 987 of SEQ ID NO:37.
[0409] In one example, the S protein (i) lacks a furin cleavage site at the S1 / S2 boundary and contains an RRAR to QQAA mutation at residues corresponding to nucleotides 682-685 of SEQ ID NO: 37, and (ii) lacks a furin cleavage site at the S2' site. For example, the mutant S protein is encoded by the sequence set forth in SEQ ID NO: 34.
[0410] In one example, the S protein (i) lacks a furin cleavage site at the S1 / S2 boundary and contains an RRAR to QQAA mutation at residues corresponding to nucleotides 682-685 of SEQ ID NO: 37, and (ii) contains a D to G mutation at residue corresponding to nucleotide 614 of SEQ ID NO: 37. For example, the mutant S protein is encoded by the sequence set forth in SEQ ID NO: 33.
[0411] In one example, the S protein (i) lacks a furin cleavage site at the S1 / S2 boundary and contains an RRAR to QQAA mutation at residues corresponding to nucleotides 682-685 of SEQ ID NO: 37, and (ii) contains an insertion of two proline residues between residues corresponding to nucleotides 986 and 987 of SEQ ID NO: 37. For example, the mutant S protein is encoded by the sequence set forth in SEQ ID NO: 32.
[0412] In one example, the S protein (i) lacks a furin cleavage site at the S1 / S2 boundary and contains an RRAR to QQAA mutation at residues corresponding to nucleotides 682-685 of SEQ ID NO: 37, and (ii) lacks a furin cleavage site at the S2' site, and (iii) contains a D to G mutation at residue corresponding to nucleotide 614 of SEQ ID NO: 37. For example, the mutant S protein is encoded by the sequence set forth in SEQ ID NO: 35.
[0413] In one embodiment, the S protein (i) lacks a furin cleavage site at the S1 / S2 boundary and contains a mutation from RRAR to QQAA at residues corresponding to nucleotides 682-685 of SEQ ID NO: 37, and (ii) lacks a furin cleavage site at the S2' site, and (iii) contains an insertion of two proline residues between residues corresponding to nucleotides 986 and 987 of SEQ ID NO: 37.
[0414] In one example, the S protein (i) lacks a furin cleavage site in the S2' region, and (ii) contains a D to G mutation at the residue corresponding to nucleotide 614 of SEQ ID NO:37.
[0415] In one example, the S protein (i) lacks a furin cleavage site at the S2' site, and (ii) contains an insertion of two proline residues between residues corresponding to nucleotides 986 and 987 of SEQ ID NO:37.
[0416] In one example, the S protein (i) lacks a furin cleavage site at the S2' site, and (ii) contains a D to G mutation at the residue corresponding to nucleotide 614 of SEQ ID NO: 37, and (iii) contains an insertion of two proline residues between the residues corresponding to nucleotides 986 and 987 of SEQ ID NO: 37.
[0417] In one example, the S protein includes (i) a D to G mutation at the residue corresponding to nucleotide 614 of SEQ ID NO: 37, and (ii) an insertion of two proline residues between the residues corresponding to nucleotides 986 and 987 of SEQ ID NO: 37.
[0418] In one embodiment, the S protein (i) lacks a furin cleavage site at the S1 / S2 boundary and contains an RRAR to QQAA mutation at residues corresponding to nucleotides 682-685 of SEQ ID NO: 37, and (ii) lacks a furin cleavage site at the S2' site and (iii) contains a D to G mutation at residue corresponding to nucleotide 614 of SEQ ID NO: 37, and (iv) contains an insertion of two proline residues between residues corresponding to nucleotides 986 and 987 of SEQ ID NO: 37.
[0419] In one example, the mutant S protein includes (i) an N to Y mutation at the residue corresponding to nucleotide 501 of SEQ ID NO: 37, and / or (ii) a deletion of two residues corresponding to nucleotides 69 and 70 of SEQ ID NO: 37, and / or (iii) a P to H mutation at the residue corresponding to nucleotide 681 of SEQ ID NO: 37.
[0420] In one example, the mutant S protein includes an N to Y mutation at the residue corresponding to nucleotide 501 of SEQ ID NO: 37, as well as a deletion of two residues corresponding to nucleotides 69 and 70 of SEQ ID NO: 37, and a P to H mutation at the residue corresponding to nucleotide 681 of SEQ ID NO: 37.
[0421] In one example, the mutant S protein comprises a P to H mutation at the residue corresponding to nucleotide 681 of SEQ ID NO:37.
[0422] In one example, the mutant S protein includes (i) a K to N mutation at the residue corresponding to nucleotide 417 of SEQ ID NO: 37, and / or (ii) an E to K mutation at the residue corresponding to nucleotide 484 of SEQ ID NO: 37, and / or (iii) an N to Y mutation at the residue corresponding to nucleotide 501 of SEQ ID NO: 37.
[0423] In one example, the mutant S protein comprises a K to N mutation at the residue corresponding to nucleotide 417 of SEQ ID NO:37.
[0424] In one example, the mutant S protein comprises an E to K mutation at the residue corresponding to nucleotide 484 of SEQ ID NO:37.
[0425] In one example, the mutant S protein includes a K to N mutation at the residue corresponding to nucleotide 417 of SEQ ID NO: 37, an E to K mutation at the residue corresponding to nucleotide 484 of SEQ ID NO: 37, and an N to Y mutation at the residue corresponding to nucleotide 501 of SEQ ID NO: 37.
[0426] In one example, the mutant S protein includes (i) a K to T mutation at the residue corresponding to nucleotide 417 of SEQ ID NO: 37, and / or (ii) an E to K mutation at the residue corresponding to nucleotide 484 of SEQ ID NO: 37, and / or (iii) an N to Y mutation at the residue corresponding to nucleotide 501 of SEQ ID NO: 37.
[0427] In one example, the mutant S protein comprises a K to T mutation at the residue corresponding to nucleotide 417 of SEQ ID NO:37.
[0428] In one example, the mutant S protein includes a K to T mutation at the residue corresponding to nucleotide 417 of SEQ ID NO: 37, an E to K mutation at the residue corresponding to nucleotide 484 of SEQ ID NO: 37, and an N to Y mutation at the residue corresponding to nucleotide 501 of SEQ ID NO: 37.
[0429] In one example, the mutant S protein comprises (i) a T to I mutation at the residue corresponding to nucleotide 95 of SEQ ID NO:37, and / or (ii) a Y to S mutation at the residue corresponding to nucleotide 144 of SEQ ID NO:37, and / or (iii) a Y to N mutation at the residue corresponding to nucleotide 145 of SEQ ID NO:37, and / or (iv) an R to K mutation at the residue corresponding to nucleotide 346 of SEQ ID NO:37, and / or (v) an E to K mutation at the residue corresponding to nucleotide 484 of SEQ ID NO:37, and / or (vi) an N to Y mutation at the residue corresponding to nucleotide 501 of SEQ ID NO:37, and / or (vii) a D to G mutation at the residue corresponding to nucleotide 614 of SEQ ID NO:37, and / or (viii) a P to H mutation at the residue corresponding to nucleotide 681 of SEQ ID NO:37, and / or (ix) a D to N mutation at the residue corresponding to nucleotide 950 of SEQ ID NO:37.
[0430] In one example, the mutant S protein comprises a T to I mutation at the residue corresponding to nucleotide 95 of SEQ ID NO:37.
[0431] In one example, the mutant S protein contains a Y to S mutation at the residue corresponding to nucleotide 144 of SEQ ID NO:37.
[0432] In one example, the mutant S protein comprises a Y to N mutation at the residue corresponding to nucleotide 145 of SEQ ID NO:37.
[0433] In one example, the mutant S protein comprises an R to K mutation at the residue corresponding to nucleotide 346 of SEQ ID NO:37.
[0434] In one example, the mutant S protein contains a D to N mutation at the residue corresponding to nucleotide 950 of SEQ ID NO:37.
[0435] In one example, the mutant S protein includes (i) a T to I mutation at the residue corresponding to nucleotide 95 of SEQ ID NO:37, and (ii) a Y to S mutation at the residue corresponding to nucleotide 144 of SEQ ID NO:37, and (iii) a Y to N mutation at the residue corresponding to nucleotide 145 of SEQ ID NO:37, and (iv) an R to K mutation at the residue corresponding to nucleotide 346 of SEQ ID NO:37, and (v) an E to K mutation at the residue corresponding to nucleotide 484 of SEQ ID NO:37, and (vi) an N to Y mutation at the residue corresponding to nucleotide 501 of SEQ ID NO:37, and (vii) a D to G mutation at the residue corresponding to nucleotide 614 of SEQ ID NO:37, (viii) a P to H mutation at the residue corresponding to nucleotide 681 of SEQ ID NO:37, and (ix) a D to N mutation at the residue corresponding to nucleotide 950 of SEQ ID NO:37.
[0436] In one example, the mutant S protein includes (i) a T to K mutation at the residue corresponding to nucleotide 478 of SEQ ID NO: 37, and / or (ii) a P to R mutation at the residue corresponding to nucleotide 681 of SEQ ID NO: 37, and / or (iii) an L to R mutation at the residue corresponding to nucleotide 452 of SEQ ID NO: 37.
[0437] In one example, the mutant S protein comprises a T to K mutation at the residue corresponding to nucleotide 478 of SEQ ID NO:37.
[0438] In one example, the mutant S protein comprises a P to R mutation at the residue corresponding to nucleotide 681 of SEQ ID NO:37.
[0439] In one example, the mutant S protein comprises an L to R mutation at the residue corresponding to nucleotide 452 of SEQ ID NO:37.
[0440] In one example, the mutant S protein includes (i) a T to K mutation at the residue corresponding to nucleotide 478 of SEQ ID NO: 37, and (ii) a P to R mutation at the residue corresponding to nucleotide 681 of SEQ ID NO: 37, and (iii) an L to R mutation at the residue corresponding to nucleotide 452 of SEQ ID NO: 37.
[0441] In one example, the S protein contains a deletion of two residues corresponding to nucleotides 69 and 70 of SEQ ID NO:37.
[0442] In one example, the S protein contains a deletion of one residue corresponding to nucleotide 144 of SEQ ID NO:37.
[0443] In one example, the S protein contains (i) an RRAR to QQAA mutation at residues corresponding to nucleotides 682-685 of SEQ ID NO: 37, and (ii) a deletion of two residues corresponding to nucleotides 69 and 70 of SEQ ID NO: 37, and (iii) a deletion of one residue corresponding to nucleotide 144 of SEQ ID NO: 37, and (iv) an N to Y mutation at residue corresponding to nucleotide 501 of SEQ ID NO: 37, and (v) a D to G mutation at residue corresponding to nucleotide 614 of SEQ ID NO: 37. For example, the mutant S protein is encoded by the sequence set forth in SEQ ID NO: 58.
[0444] In one example, the S protein contains a deletion of three residues corresponding to nucleotides 242-244 of SEQ ID NO:37.
[0445] In one example, the S protein contains (i) an RRAR to QQAA mutation at residues corresponding to nucleotides 682-685 of SEQ ID NO: 37, and (ii) a deletion of three residues corresponding to nucleotides 242-244 of SEQ ID NO: 37, and (iii) a K to N mutation at residue corresponding to nucleotide 417 of SEQ ID NO: 37, and (iv) an E to K mutation at residue corresponding to nucleotide 484 of SEQ ID NO: 37, and (v) an N to Y mutation at residue corresponding to nucleotide 501 of SEQ ID NO: 37, and (vi) a D to G mutation at residue corresponding to nucleotide 614 of SEQ ID NO: 37. For example, the mutant S protein is encoded by the sequence set forth in SEQ ID NO: 59.
[0446] In one example, the S protein comprises (i) an RRAR to QQAA mutation at residues corresponding to nucleotides 682-685 of SEQ ID NO: 37, (ii) a deletion of two residues corresponding to nucleotides 69 and 70 of SEQ ID NO: 37, (iii) a deletion of three residues corresponding to nucleotides 242-244 of SEQ ID NO: 37, (iv) a K to N mutation at residue corresponding to nucleotide 417 of SEQ ID NO: 37, (v) an E to K mutation at residue corresponding to nucleotide 484 of SEQ ID NO: 37, (vi) an N to Y mutation at residue corresponding to nucleotide 501 of SEQ ID NO: 37, and (vii) a D to G mutation at residue corresponding to nucleotide 614 of SEQ ID NO: 37. For example, the mutant S protein is encoded by the sequence set forth in SEQ ID NO: 60.
[0447] In one example, the S protein includes an A to D mutation at the residue corresponding to nucleotide 570 of SEQ ID NO:37.
[0448] In one example, the S protein includes a P to H mutation at the residue corresponding to nucleotide 680 of SEQ ID NO:37.
[0449] In one example, the S protein includes a T to I mutation at the residue corresponding to nucleotide 716 of SEQ ID NO:37.
[0450] In one example, the S protein comprises (i) an RRAR to QQAA mutation at residues corresponding to nucleotides 682-685 of SEQ ID NO:37, (ii) a deletion of two residues corresponding to nucleotides 69 and 70 of SEQ ID NO:37, (iii) a deletion of one residue corresponding to nucleotide 144 of SEQ ID NO:37, (iv) an N to Y mutation at a residue corresponding to nucleotide 501 of SEQ ID NO:37, (v) an A to D mutation at a residue corresponding to nucleotide 570 of SEQ ID NO:37, (vi) a D to G mutation at a residue corresponding to nucleotide 614 of SEQ ID NO:37, (vii) a P to H mutation at a residue corresponding to nucleotide 680 of SEQ ID NO:37, and (viii) a T to I mutation at a residue corresponding to nucleotide 716 of SEQ ID NO:37. For example, the mutant S protein is encoded by the sequence set forth in SEQ ID NO:61.
[0451] In one example, the S protein includes an L to F mutation at the residue corresponding to nucleotide 18 of SEQ ID NO:37.
[0452] In one example, the S protein includes a D to A mutation at the residue corresponding to nucleotide 80 of SEQ ID NO:37.
[0453] In one example, the S protein includes a D to G mutation at the residue corresponding to nucleotide 215 of SEQ ID NO:37.
[0454] In one example, the S protein includes an A to V mutation at the residue corresponding to nucleotide 701 of SEQ ID NO:37.
[0455] In one example, the S protein comprises (i) an RRAR to QQAA mutation at residues corresponding to nucleotides 682-685 of SEQ ID NO:37, (ii) an L to F mutation at residues corresponding to nucleotide 18 of SEQ ID NO:37, (iii) a D to A mutation at residues corresponding to nucleotide 80 of SEQ ID NO:37, (iv) a D to G mutation at residues corresponding to nucleotide 215 of SEQ ID NO:37, and (v) a deletion of three residues corresponding to nucleotides 242-244 of SEQ ID NO:37, (vi) a K to N mutation at residues corresponding to nucleotide 417 of SEQ ID NO:37, and (vii) an E to K mutation at residues corresponding to nucleotide 484 of SEQ ID NO:37, and (viii) an N to Y mutation at residues corresponding to nucleotide 501 of SEQ ID NO:37, and (ix) a D to G mutation at residues corresponding to nucleotide 614 of SEQ ID NO:37, and (x) an A to V mutation at residues corresponding to nucleotide 701 of SEQ ID NO:37. For example, the mutant S protein is encoded by the sequence set forth in SEQ ID NO:62.
[0456] In one example, the mutant S protein (i) lacks a furin cleavage site at the S1 / S2 boundary and comprises an RRAR to QQAA mutation at residues corresponding to nucleotides 682-685 of SEQ ID NO: 37, and / or (ii) lacks a furin cleavage site at the S2' site, and / or (iii) comprises a D to G mutation at residue corresponding to nucleotide 614 of SEQ ID NO: 37, and / or (iv) comprises an insertion of two proline residues between residues corresponding to nucleotides 986 and 987 of SEQ ID NO: 37, and / or (v) comprises an N to Y mutation at residue corresponding to nucleotide 501 of SEQ ID NO: 37, and / or (vi) comprises a deletion of two residues corresponding to nucleotides 69 and 70 of SEQ ID NO: 37, and / or (vii) comprises a deletion of one residue corresponding to nucleotide 144 of SEQ ID NO: 37, and / or (viii) comprises a deletion of three residues corresponding to nucleotides 242-244 of SEQ ID NO: 37, and / or (ix) a K to N mutation at the residue corresponding to nucleotide 417 of SEQ ID NO:37, and / or (x) an E to K mutation at the residue corresponding to nucleotide 484 of SEQ ID NO:37, and / or (xi) an A to D mutation at the residue corresponding to nucleotide 570 of SEQ ID NO:37, and / or (xii) a P to H mutation at the residue corresponding to nucleotide 680 of SEQ ID NO:37, and / or (xiii) a T to I mutation at the residue corresponding to nucleotide 716 of SEQ ID NO:37, and / or (xix) an L to F mutation at the residue corresponding to nucleotide 18 of SEQ ID NO:37, and / or (xx), and / or a D to A mutation at the residue corresponding to nucleotide 80 of SEQ ID NO:37, and / or (xxi) a D to G mutation at the residue corresponding to nucleotide 215 of SEQ ID NO:37, and / or (xxii) an A to V mutation at the residue corresponding to nucleotide 701 of SEQ ID NO:37.
[0457] In one embodiment, the mutant S protein is encoded by the sequence set forth in SEQ ID NO: 9 or any one of SEQ ID NOs: 32-36.
[0458] In one embodiment, the mutant S protein is encoded by the sequence set forth in any one of SEQ ID NO: 9, SEQ ID NOs: 32-36, or SEQ ID NOs: 58-62.
[0459] In one embodiment, the mutant S protein is encoded by the sequence set forth in SEQ ID NO:9.
[0460] In one example, the mutant S protein is encoded by the sequence set forth in SEQ ID NO:32.
[0461] In one example, the mutant S protein is encoded by the sequence set forth in SEQ ID NO:33.
[0462] In one embodiment, the mutant S protein is encoded by the sequence set forth in SEQ ID NO:34.
[0463] In one example, the mutant S protein is encoded by the sequence set forth in SEQ ID NO:35.
[0464] In one example, the mutant S protein is encoded by the sequence set forth in SEQ ID NO:36.
[0465] In one example, the mutant S protein is encoded by the sequence set forth in SEQ ID NO:58.
[0466] In one example, the mutant S protein is encoded by the sequence set forth in SEQ ID NO:59.
[0467] In one example, the mutant S protein is encoded by the sequence set forth in SEQ ID NO:60.
[0468] In one example, the mutant S protein is encoded by the sequence set forth in SEQ ID NO:61.
[0469] In one example, the mutant S protein is encoded by the sequence set forth in SEQ ID NO:62.
[0470] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an S protein and a second nucleotide sequence encoding an N protein; or b) comprises a first nucleotide sequence encoding an N protein and a second nucleotide sequence encoding an S protein.
[0471] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order, a first nucleotide sequence encoding an S protein and a second nucleotide sequence encoding an N protein.
[0472] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order, a first nucleotide sequence encoding an S protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof, and a second nucleotide sequence encoding an N protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0473] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order, a first nucleotide sequence encoding an N protein and a second nucleotide sequence encoding an S protein.
[0474] In one example, the disclosure provides a polynucleotide, the polynucleotide comprising, in 5' to 3' order, a first nucleotide sequence encoding an N protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof, and a second nucleotide sequence encoding an S protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0475] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an S protein and a second nucleotide sequence encoding an N protein; or b) comprises a first nucleotide sequence encoding an N protein and a second nucleotide sequence encoding an S protein.
[0476] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an S protein and a second nucleotide sequence encoding an N protein.
[0477] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an S protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof, and a second nucleotide sequence encoding an N protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0478] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an N protein and a second nucleotide sequence encoding an S protein.
[0479] In one example, the disclosure provides an RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an N protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof, and a second nucleotide sequence encoding an S protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0480] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an S protein and a second nucleotide sequence encoding an N protein; or b) comprises a first nucleotide sequence encoding an N protein and a second nucleotide sequence encoding an S protein.
[0481] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an S protein and a second nucleotide sequence encoding an N protein.
[0482] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an S protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof, and a second nucleotide sequence encoding an N protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0483] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an N protein and a second nucleotide sequence encoding an S protein.
[0484] In one example, the disclosure provides a cRNA, the cRNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an N protein operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof, and a second nucleotide sequence encoding an S protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0485] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an S protein and a second nucleotide sequence encoding an N protein; or b) comprises a first nucleotide sequence encoding an N protein and a second nucleotide sequence encoding an S protein.
[0486] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an S protein and a second nucleotide sequence encoding an N protein.
[0487] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an S protein operably linked to an SG promoter, and a second nucleotide sequence encoding an N protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0488] In one embodiment, the disclosure provides a multicistronic self-replicating RNA molecule, the molecule comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an S protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and b) A second nucleotide sequence encoding an N protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1.
[0489] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an S protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and b) A second nucleotide sequence encoding an N protein operably linked to an extended SG promoter encoded by the sequence set forth in SEQ ID NO:2.
[0490] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an S protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and b) A second nucleotide sequence encoding an N protein operably linked to an extended SG promoter encoded by the sequence set forth in SEQ ID NO:3.
[0491] In one embodiment, the disclosure provides a multicistronic self-replicating RNA molecule, the molecule comprising, in 5' to 3' order: a) a first nucleotide sequence encoding a mutated S protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and b) A second nucleotide sequence encoding an N protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1.
[0492] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding a mutated S protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and b) A second nucleotide sequence encoding an N protein operably linked to an extended SG promoter encoded by the sequence set forth in SEQ ID NO:2.
[0493] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding a mutated S protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and b) A second nucleotide sequence encoding an N protein operably linked to an extended SG promoter encoded by the sequence set forth in SEQ ID NO:3.
[0494] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an S protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and b) comprises a second nucleotide sequence encoding an N protein operably linked to an IRES encoded by the sequence set forth in SEQ ID NO:4.
[0495] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an N protein and a second nucleotide sequence encoding an S protein.
[0496] In one example, the disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order, a first nucleotide sequence encoding an N protein operably linked to an SG promoter, and a second nucleotide sequence encoding an S protein operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0497] In one embodiment, the disclosure provides a multicistronic self-replicating RNA molecule, the molecule comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an N protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and b) A second nucleotide sequence encoding an S protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1.
[0498] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an N protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and b) A second nucleotide sequence encoding an S protein operably linked to an extended SG promoter encoded by the sequence set forth in SEQ ID NO:2.
[0499] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an N protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and b) A second nucleotide sequence encoding an S protein operably linked to an extended SG promoter encoded by the sequence set forth in SEQ ID NO:3.
[0500] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA, the RNA comprising, in 5' to 3' order: a) a first nucleotide sequence encoding an N protein operably linked to a minimal SG promoter encoded by the sequence set forth in SEQ ID NO:1; and b) comprises a second nucleotide sequence encoding an S protein operably linked to an IRES encoded by the sequence set forth in SEQ ID NO:4.
[0501] In one embodiment, the present disclosure provides a multicistronic self-replicating RNA encoded by a sequence set forth in any one of SEQ ID NOS: 10-14, 19-27, or 30-31. In one embodiment, the present disclosure provides a multicistronic self-replicating RNA encoded by a sequence set forth in any one of SEQ ID NOS: 10-14, 19-27, 30-31, or 49-53. For example, the present disclosure provides a multicistronic self-replicating RNA encoded by a sequence set forth in any one of SEQ ID NOS: 10-14 or 19-27. In another embodiment, the present disclosure provides a multicistronic self-replicating RNA encoded by a sequence set forth in any one of SEQ ID NOS: 30-31. In another embodiment, the present disclosure provides a multicistronic self-replicating RNA encoded by a sequence set forth in any one of SEQ ID NOS: 49-53.
[0502] In one example, the present disclosure provides a multicistronic self-replicating RNA encoded by the sequence set forth in SEQ ID NO: 10 (F548).
[0503] In one example, the present disclosure provides a multicistronic self-replicating RNA encoded by the sequence set forth in SEQ ID NO: 11 (F549).
[0504] In one example, the present disclosure provides a multicistronic self-replicating RNA encoded by the sequence set forth in SEQ ID NO: 12 (F556).
[0505] In one example, the present disclosure provides a multicistronic self-replicating RNA encoded by the sequence set forth in SEQ ID NO: 13 (F557).
[0506] In one example, the present disclosure provides a multicistronic self-replicating RNA encoded by the sequence set forth in SEQ ID NO: 14 (F602).
[0507] In one example, the present disclosure provides a multicistronic self-replicating RNA encoded by the sequence set forth in SEQ ID NO: 19 (F554).
[0508] In one example, the present disclosure provides a multicistronic self-replicating RNA encoded by the sequence set forth in SEQ ID NO: 20 (F568).
[0509] In one example, the present disclosure provides a multicistronic self-replicating RNA encoded by the sequence set forth in SEQ ID NO: 21 (F569).
[0510] In one example, the present disclosure provides a multicistronic self-replicating RNA encoded by the sequence set forth in SEQ ID NO: 22 (F570).
[0511] In one example, the present disclosure provides a multicistronic self-replicating RNA encoded by the sequence set forth in SEQ ID NO: 23 (F576).
[0512] In one example, the present disclosure provides a multicistronic self-replicating RNA encoded by the sequence set forth in SEQ ID NO: 24 (F584).
[0513] In one example, the present disclosure provides a multicistronic self-replicating RNA encoded by the sequence set forth in SEQ ID NO: 25 (F590).
[0514] In one example, the present disclosure provides a multicistronic self-replicating RNA encoded by the sequence set forth in SEQ ID NO: 26 (F616).
[0515] In one example, the present disclosure provides a multicistronic self-replicating RNA encoded by the sequence set forth in SEQ ID NO: 27 (F620).
[0516] In one example, the present disclosure provides a multicistronic self-replicating RNA encoded by the sequence set forth in SEQ ID NO: 30 (Co18).
[0517] In one example, the present disclosure provides a multicistronic self-replicating RNA encoded by the sequence set forth in SEQ ID NO: 31 (Co19).
[0518] In one example, the present disclosure provides a multicistronic self-replicating RNA encoded by the sequence set forth in SEQ ID NO: 49 (F631).
[0519] In one example, the present disclosure provides a multicistronic self-replicating RNA encoded by the sequence set forth in SEQ ID NO: 50 (F632).
[0520] In one example, the present disclosure provides a multicistronic self-replicating RNA encoded by the sequence set forth in SEQ ID NO: 51 (F629).
[0521] In one example, the present disclosure provides a multicistronic self-replicating RNA encoded by the sequence set forth in SEQ ID NO: 52 (F695).
[0522] In one example, the present disclosure provides a multicistronic self-replicating RNA encoded by the sequence set forth in SEQ ID NO: 53 (703).
[0523] The present disclosure provides an immunogenic composition comprising a polynucleotide of the present disclosure. The present disclosure further provides an immunogenic composition comprising an RNA of the present disclosure. For example, the present disclosure provides an immunogenic composition comprising a cRNA of the present disclosure. The present disclosure also provides an immunogenic composition comprising a self-replicating RNA of the present disclosure. For example, the composition of the present disclosure, when administered, can induce an immune response in a subject. For example, administration of the composition induces a humoral and / or cell-mediated immune response. In one example, the composition induces a humoral immune response in a subject. For example, the humoral immune response is an antibody-mediated immune response. In another example, the composition induces a cell-mediated immune response. For example, the cell-mediated immune response includes activation of antigen-specific cytotoxic T cells.
[0524] In one example, the immunogenic composition of the present disclosure comprises a plurality of polynucleotides, each polynucleotide encoding a different polypeptide antigen sequence. In another example, the immunogenic composition of the present disclosure comprises a plurality of RNAs, each RNA encoding a different polypeptide antigen sequence. In a further example, the immunogenic composition of the present disclosure comprises a plurality of cRNAs, each cRNA encoding a different polypeptide antigen sequence. In one example, the immunogenic composition comprises a plurality of multicistronic self-replicating RNAs, each multicistronic self-replicating RNA encoding a different polypeptide antigen sequence. For example, the different polypeptide antigen sequences are derived from the same virus (e.g., encoding antigens from the same influenza A virus strain). In one example, the different polypeptide antigen sequences are derived from different viruses. For example, the sequences encode different influenza A virus strains.
[0525] The present disclosure also provides a pharmaceutical composition comprising an immunogenic composition of the present disclosure and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers suitable for use in the present disclosure will be apparent to those of skill in the art and / or are described herein.
[0526] In one embodiment, the pharmaceutical composition further comprises lipid nanoparticles (LNPs), polymeric microparticles, and oil-in-water emulsions. For example, polynucleotides, RNA, cRNA, or self-replicating RNA are encapsulated in, bound to, or adsorbed to the LNPs, polymeric microparticles, and oil-in-water emulsions. In one embodiment, polynucleotides are encapsulated in, bound to, or adsorbed to the LNPs, polymeric microparticles, and oil-in-water emulsions. In another embodiment, RNA is encapsulated in, bound to, or adsorbed to the LNPs, polymeric microparticles, and oil-in-water emulsions. For example, cRNA is encapsulated in, bound to, or adsorbed to the LNPs, polymeric microparticles, and oil-in-water emulsions. For example, self-replicating RNA is encapsulated in, bound to, or adsorbed to the LNPs, polymeric microparticles, and oil-in-water emulsions.
[0527] In one embodiment, the pharmaceutical composition further comprises an LNP. For example, a polynucleotide is encapsulated in the LNP. In another embodiment, RNA is encapsulated in the LNP. For example, cRNA is encapsulated in the LNP. For example, self-replicating RNA is encapsulated in the LNP. For example, a polynucleotide is bound to the LNP. In another embodiment, RNA is bound to the LNP. For example, cRNA is bound to the LNP. In another embodiment, self-replicating RNA is bound to the LNP. For example, a polynucleotide is adsorbed to the LNP. In another embodiment, RNA is adsorbed to the LNP. For example, cRNA is adsorbed to the LNP. In a further embodiment, self-replicating RNA is adsorbed to the LNP.
[0528] In one embodiment, the LNPs comprise PEG-lipids, structured lipids, and / or neutral lipids. For example, the LNPs comprise PEG-lipids, structured lipids, and neutral lipids. In another embodiment, the LNPs comprise PEG-lipids, structured lipids, or neutral lipids.
[0529] In one embodiment, the LNPs further comprise a cationic lipid. In another embodiment, the LNPs do not comprise a cationic lipid.
[0530] In one embodiment, the pharmaceutical composition further comprises polymeric microparticles. For example, a polynucleotide is encapsulated in the polymeric microparticles. In another embodiment, RNA is encapsulated in the polymeric microparticles. For example, cRNA is encapsulated in the polymeric microparticles. For example, self-replicating RNA is encapsulated in the polymeric microparticles. For example, a polynucleotide is bound to the polymeric microparticles. In another embodiment, RNA is bound to the polymeric microparticles. For example, cRNA is bound to the polymeric microparticles. In another embodiment, self-replicating RNA is bound to the polymeric microparticles. For example, a polynucleotide is adsorbed to the polymeric microparticles. In another embodiment, RNA is adsorbed to the polymeric microparticles. For example, cRNA is adsorbed to the polymeric microparticles. In a further embodiment, self-replicating RNA is adsorbed to the polymeric microparticles.
[0531] In one embodiment, the pharmaceutical composition further comprises an oil-in-water emulsion. For example, the polynucleotide is encapsulated in the oil-in-water emulsion. In another embodiment, the RNA is encapsulated in the oil-in-water emulsion. For example, the cRNA is encapsulated in the oil-in-water emulsion. For example, the self-replicating RNA is encapsulated in the oil-in-water emulsion. For example, the polynucleotide is bound to the oil-in-water emulsion. In another embodiment, the RNA is bound to the oil-in-water emulsion. For example, the cRNA is bound to the oil-in-water emulsion. In another embodiment, the self-replicating RNA is bound to the oil-in-water emulsion. In a further embodiment, the self-replicating RNA is adsorbed to the oil-in-water emulsion. In a further embodiment, the self-replicating RNA is resuspended in the oil-in-water emulsion.
[0532] The present disclosure also provides an immunogenic or pharmaceutical composition of the present disclosure for use as a vaccine.
[0533] In one embodiment, the polynucleotide is DNA. In one embodiment, the present disclosure provides DNA encoding a cRNA vaccine of the present disclosure. In one embodiment, the present disclosure provides DNA encoding a self-replicating RNA vaccine of the present disclosure.
[0534] In one embodiment, the DNA is a plasmid.
[0535] The present disclosure further provides an immunogenic or pharmaceutical composition of the present disclosure for use in treating or preventing, or slowing the progression of, a respiratory viral infection. For example, the present disclosure provides an immunogenic or pharmaceutical composition of the present disclosure for use in treating a respiratory viral infection. In one example, the present disclosure provides an immunogenic or pharmaceutical composition of the present disclosure for use in preventing a respiratory viral infection. In another example, the present disclosure provides an immunogenic or pharmaceutical composition of the present disclosure for use in slowing the progression of a respiratory viral infection. For example, the immunogenic or pharmaceutical composition of the present disclosure is for use in treating, preventing, or slowing the progression of influenza, influenza virus infection, bronchiolitis, pneumonia, croup, SARS-CoV-2 infection, COVID-19, and / or ARDS. In one example, the immunogenic or pharmaceutical composition of the disclosure is for use in treating, preventing, or delaying the progression of influenza, influenza virus infection, SARS-CoV-2 infection, COVID, and / or ARDS.
[0536] In one example, the present disclosure provides an immunogenic or pharmaceutical composition of the present disclosure for use in treating, preventing, or delaying the progression of influenza. For example, the present disclosure provides an immunogenic or pharmaceutical composition of the present disclosure for use in treating influenza. In another example, the present disclosure provides an immunogenic or pharmaceutical composition of the present disclosure for use in preventing influenza. In a further example, the present disclosure provides an immunogenic or pharmaceutical composition of the present disclosure for use in delaying the progression of influenza.
[0537] In one example, the present disclosure provides an immunogenic or pharmaceutical composition of the present disclosure for use in treating, preventing, or slowing the progression of influenza virus infection. For example, the present disclosure provides an immunogenic or pharmaceutical composition of the present disclosure for use in treating influenza virus infection. In another example, the present disclosure provides an immunogenic or pharmaceutical composition of the present disclosure for use in preventing influenza virus infection. In a further example, the present disclosure provides an immunogenic or pharmaceutical composition of the present disclosure for use in slowing the progression of influenza virus infection.
[0538] In one example, the present disclosure provides an immunogenic or pharmaceutical composition of the present disclosure for use in treating, preventing, or slowing the progression of COVID-19. For example, the present disclosure provides an immunogenic or pharmaceutical composition of the present disclosure for use in treating COVID-19. In another example, the present disclosure provides an immunogenic or pharmaceutical composition of the present disclosure for use in preventing COVID-19. In a further example, the present disclosure provides an immunogenic or pharmaceutical composition of the present disclosure for use in slowing the progression of COVID-19.
[0539] In one example, the present disclosure provides an immunogenic or pharmaceutical composition of the present disclosure for use in treating, preventing, or slowing the progression of SARS-CoV-2 infection. For example, the present disclosure provides an immunogenic or pharmaceutical composition of the present disclosure for use in treating SARS-CoV-2 infection. In another example, the present disclosure provides an immunogenic or pharmaceutical composition of the present disclosure for use in preventing SARS-CoV-2 infection. In a further example, the present disclosure provides an immunogenic or pharmaceutical composition of the present disclosure for use in slowing the progression of SARS-CoV-2 infection.
[0540] In one example, the present disclosure provides an immunogenic or pharmaceutical composition of the present disclosure for use in treating, preventing, or slowing the progression of ARDS. For example, the present disclosure provides an immunogenic or pharmaceutical composition of the present disclosure for use in treating ARDS. In another example, the present disclosure provides an immunogenic or pharmaceutical composition of the present disclosure for use in preventing ARDS. In a further example, the present disclosure provides an immunogenic or pharmaceutical composition of the present disclosure for use in slowing the progression of ARDS.
[0541] The present disclosure provides a method for treating or preventing, or delaying the progression of, a disease or condition in a subject, comprising administering to a subject in need thereof an immunogenic or pharmaceutical composition of the present disclosure. In one example, the present disclosure provides a method for treating a disease or condition in a subject, comprising administering to a subject in need thereof an immunogenic or pharmaceutical composition of the present disclosure. In another example, the present disclosure provides a method for preventing a disease or condition in a subject, comprising administering to a subject in need thereof an immunogenic or pharmaceutical composition of the present disclosure. In a further example, the present disclosure provides a method for delaying the progression of a disease or condition in a subject, comprising administering to a subject in need thereof an immunogenic or pharmaceutical composition of the present disclosure.
[0542] In one example, the disclosure provides the use of a polynucleotide of this disclosure in the manufacture of a medicament for treating or preventing, or slowing the progression of, a disease or condition in a subject in need thereof. For example, the disclosure provides the use of a polynucleotide of this disclosure in the manufacture of a medicament for treating, preventing, or slowing the progression of a disease or condition in a subject in need thereof. In another example, the disclosure provides the use of a polynucleotide of this disclosure in the manufacture of a medicament for preventing, a disease or condition in a subject in need thereof. In a further example, the disclosure provides the use of a polynucleotide of this disclosure in the manufacture of a medicament for slowing the progression of a disease or condition in a subject in need thereof.
[0543] In one example, the disclosure provides the use of an RNA of the disclosure in the manufacture of a medicament for treating or preventing, or slowing the progression of, a disease or condition in a subject in need thereof. For example, the disclosure provides the use of an RNA of the disclosure in the manufacture of a medicament for treating, preventing, or slowing the progression of a disease or condition in a subject in need thereof. In another example, the disclosure provides the use of an RNA of the disclosure in the manufacture of a medicament for preventing, preventing, or slowing the progression of a disease or condition in a subject in need thereof. In a further example, the disclosure provides the use of an RNA of the disclosure in the manufacture of a medicament for slowing the progression of a disease or condition in a subject in need thereof.
[0544] In one example, the disclosure provides the use of a cRNA of this disclosure in the manufacture of a medicament for treating or preventing a disease or condition, or slowing its progression in a subject in need thereof. For example, the disclosure provides the use of a cRNA of this disclosure in the manufacture of a medicament for treating a disease or condition in a subject in need thereof. In another example, the disclosure provides the use of a cRNA of this disclosure in the manufacture of a medicament for preventing a disease or condition in a subject in need thereof. In a further example, the disclosure provides the use of a cRNA of this disclosure in the manufacture of a medicament for slowing the progression of a disease or condition in a subject in need thereof.
[0545] In one example, the present disclosure provides the use of a self-replicating RNA of the present disclosure in the manufacture of a medicament for treating or preventing, or slowing the progression of, a disease or condition in a subject in need thereof. For example, the present disclosure provides the use of a self-replicating RNA of the present disclosure in the manufacture of a medicament for treating a disease or condition in a subject in need thereof. In another example, the present disclosure provides the use of a self-replicating RNA of the present disclosure in the manufacture of a medicament for preventing a disease or condition in a subject in need thereof. In a further example, the present disclosure provides the use of a self-replicating RNA of the present disclosure in the manufacture of a medicament for slowing the progression of a disease or condition in a subject in need thereof.
[0546] In one embodiment, the subject is suffering from a disease or condition. In one embodiment, the subject has been diagnosed with a disease or condition. In one embodiment, the subject is receiving treatment for a disease or condition.
[0547] In one embodiment, the disease or condition is a respiratory viral infection. For example, the respiratory viral infection is selected from the group consisting of influenza, influenza virus infection, bronchiolitis, pneumonia, croup, SARS-CoV-2 infection, COVID-19, and ARDS. In one embodiment, the disease or condition is influenza, influenza virus infection, SARS-CoV-2 infection, COVID-19, and / or ARDS. In one embodiment, the disease or condition is influenza. In another embodiment, the disease or condition is influenza virus infection. In another embodiment, the disease or condition is bronchiolitis. In a further embodiment, the disease or condition is pneumonia. In one embodiment, the disease or condition is croup. In another embodiment, the disease or condition is SARS-CoV-2 infection. In another embodiment, the disease or condition is COVID-19. In a further embodiment, the disease or condition is ARDS. In one embodiment, the ARDS is associated with influenza, influenza virus infection, SARS-CoV-2 infection, and / or COVID-19.
[0548] In one embodiment of any method described herein, the self-replicating RNA of the disclosure is administered before or after the onset of influenza, influenza virus infection, SARS-CoV-2 infection, COVID-19, and / or ARDS in a subject. In one embodiment of any method described herein, the self-replicating RNA of the disclosure is administered before the onset of influenza, influenza virus infection, SARS-CoV-2 infection, COVID-19, and / or ARDS in a subject. In one embodiment of any method described herein, the self-replicating RNA of the disclosure is administered after the onset of influenza, influenza virus infection, SARS-CoV-2 infection, COVID-19, and / or ARDS in a subject.
[0549] In one embodiment of any method described herein, the self-replicating RNA of the present disclosure is administered after detection of a respiratory viral infection. For example, the self-replicating RNA of the present disclosure is administered after detection of influenza, influenza virus infection, SARS-CoV-2 infection, COVID-19, and / or ARDS in a subject. In one embodiment of any method described herein, the self-replicating RNA of the present disclosure is administered after detection of influenza, influenza virus infection, SARS-CoV-2 infection, COVID-19, and / or ARDS in a subject. In a further embodiment of any method described herein, the self-replicating RNA of the present disclosure is administered after detection of an influenza virus infection. In one embodiment of any method described herein, the self-replicating RNA of the present disclosure is administered after detection of an influenza virus infection but before the onset of influenza. In another embodiment of any method described herein, the self-replicating RNA of the present disclosure is administered after detection of a SARS-CoV-2 infection. In one embodiment, the self-replicating RNA of the present disclosure is administered after detection of a SARS-CoV-2 infection but before the onset of COVID-19. In further embodiments of any of the methods described herein, the self-replicating RNA of the present disclosure is administered after detection of COVID-19. In one embodiment of any of the methods described herein, the self-replicating RNA of the present disclosure is administered after detection of COVID-19 but before the onset of ARDS. In another embodiment of any of the methods described herein, the self-replicating RNA of the present disclosure is administered after detection of ARDS.
[0550] In one embodiment, the subject is at risk of developing influenza, COVID-19, or ARDS. For example, the subject is at risk of developing influenza. In another embodiment, the subject is at risk of developing COVID-19. In a further embodiment, the subject is at risk of developing ARDS.
[0551] In one example, the compositions of the present disclosure are administered in an amount sufficient to reduce the severity of or prevent the occurrence of one or more symptoms of influenza, influenza virus infection, SARS-CoV-2 infection, COVID-19, and / or ARDS, the symptoms of which will be apparent to one of skill in the art and / or described herein.
[0552] The present disclosure provides a method of inducing an immune response in a subject, the method comprising administering a self-replicating RNA, immunogenic composition, or pharmaceutical composition of the present disclosure to a subject in need thereof.
[0553] The present disclosure also provides the use of a self-replicating RNA, immunogenic composition, or pharmaceutical composition of the present disclosure in the manufacture of a medicament for inducing an immune response in a subject in need thereof.
[0554] In one example, the self-replicating RNA, immunogenic composition, or pharmaceutical composition of the present disclosure induces a humoral and / or cell-mediated immune response. In one example, the composition induces a humoral immune response in a subject. For example, the humoral immune response is an antibody-mediated immune response, such as the production of neutralizing antibodies. In another example, the composition induces a cell-mediated immune response. For example, the cell-mediated immune response includes the activation of antigen-specific cytotoxic T cells. For example, the T cells are CD4 T cells and / or CD8 T cells. In one example, the T cells are CD4 T cells. In another example, the T cells are CD8 T cells. In a further example, the T cells are CD4 and CD8 T cells.
[0555] In one example, administration of a self-replicating RNA, immunogenic composition, or pharmaceutical composition of the disclosure induces a CD4 T cell-mediated immune response.
[0556] In one example, administration of a self-replicating RNA, immunogenic composition, or pharmaceutical composition of the disclosure induces a CD8 T cell-mediated immune response.
[0557] In one example, administration of a self-replicating RNA, immunogenic composition, or pharmaceutical composition of the disclosure induces a CD4 and CD8 T cell-mediated immune response.
[0558] The present disclosure also provides a polynucleotide encoding the self-replicating RNA of the present disclosure. For example, the polynucleotide is recombinant DNA. In one embodiment, the recombinant DNA is a plasmid. In one embodiment, the plasmid comprises a sequence set forth in any one of SEQ ID NOs: 10-14, 19-27, or 30-31.
[0559] The present disclosure also provides kits comprising at least one self-replicating RNA of the present disclosure, optionally in a delivery system and / or a pharmaceutically acceptable carrier or diluent, packaged with instructions for use for use in treating, preventing, or slowing the progression of a disease or disorder (e.g., influenza, influenza virus infection, SARS-CoV-2 infection, COVID-19, and / or ARDS) in a subject.
[0560] The present disclosure also provides kits comprising at least one self-replicating RNA of the present disclosure, optionally in a delivery system and / or a pharmaceutically acceptable carrier or diluent, packaged with instructions for administering the RNA to a subject suffering from or at risk of suffering from a disease or disorder (e.g., influenza, influenza virus infection, SARS-CoV-2 infection, COVID-19, and / or ARDS).
[0561] In one example, the self-replicating RNA, immunogenic composition, or pharmaceutical composition of the present disclosure is supplied in a vial, hi another example, the self-replicating RNA, immunogenic composition, or pharmaceutical composition of the present disclosure is supplied in a syringe. [Brief explanation of the drawings]
[0562] [Figure 1] (A) Schematic diagram of self-replicating RNA prepared using HA and NA subtypes from A / turkey / Turkey / 1 / 2005. (B) and (C) show 5' cap-driven antigen expression in the construct. [Figure 2-1] 1 shows the pattern of gene expression of the H5 and N1 genes of interest in unformulated RNA constructs (A) F548 (B) F549 (C) F602 (D) F616 (E) F556 (F) F557 (G) F568 (H) F569 (I) F576 (J) F620 (K) F584 (L) F590 as determined by mean fluorescence intensity (MFI) analysis. [Figure 2-2] 1 shows the pattern of gene expression of the H5 and N1 genes of interest in unformulated RNA constructs (A) F548 (B) F549 (C) F602 (D) F616 (E) F556 (F) F557 (G) F568 (H) F569 (I) F576 (J) F620 (K) F584 (L) F590 as determined by mean fluorescence intensity (MFI) analysis. [Figure 2-3] 1 shows the pattern of gene expression of the H5 and N1 genes of interest in unformulated RNA constructs (A) F548 (B) F549 (C) F602 (D) F616 (E) F556 (F) F557 (G) F568 (H) F569 (I) F576 (J) F620 (K) F584 (L) F590 as determined by mean fluorescence intensity (MFI) analysis. [Figure 3-1]1 shows the pattern of gene expression of a first and second gene of interest for RNA formulated in lipid nanoparticles as determined by mean fluorescence intensity analysis. (A) Expression of H5 and N1 antigens in the F556 and F548 constructs. (B) Expression of H5 and N1 antigens in the F557 and F549 constructs. (C) Expression of H5 antigen in the F556, F602, and F616 constructs compared to the control construct F500.3, which expresses only the H5 antigen. (D) Expression of N1 antigen in the F556, F602, and F616 constructs compared to the control construct F543, which expresses only the N1 antigen. (E) Expression of H5, N1, and M1 antigens in the F554 construct. (F) Expression of H5, N1, and M1 antigens in the F584 construct. (G) Expression of H5, N1, M1, and M2 antigens in the F590 construct. [Figure 3-2] 1 shows the pattern of gene expression of a first and second gene of interest for RNA formulated in lipid nanoparticles as determined by mean fluorescence intensity analysis. (A) Expression of H5 and N1 antigens in the F556 and F548 constructs. (B) Expression of H5 and N1 antigens in the F557 and F549 constructs. (C) Expression of H5 antigen in the F556, F602, and F616 constructs compared to the control construct F500.3, which expresses only the H5 antigen. (D) Expression of N1 antigen in the F556, F602, and F616 constructs compared to the control construct F543, which expresses only the N1 antigen. (E) Expression of H5, N1, and M1 antigens in the F554 construct. (F) Expression of H5, N1, and M1 antigens in the F584 construct. (G) Expression of H5, N1, M1, and M2 antigens in the F590 construct. [Figure 4] Microneutralization titers from mice immunized with self-replicating RNA in (A) short and (B) long form microneutralization assays are shown. [Figure 5] Hemagglutinin titers from mice immunized with self-replicating RNA are shown. [Figure 6]Antigen-specific CD4 and CD8 T cell responses are shown. (A) H5- and N1-antigen-specific CD8 T cell responses in F548, F549, F556, and F557. (B) H5- and N1-antigen-specific CD8 T cell responses in F556, F557, F602, and F616. (C) H5- and N1-antigen-specific CD4 T cell responses in F548, F549, F556, and F557. (D) H5- and N1-antigen-specific CD4 T cell responses in F556, F557, F602, and F616. [Figure 7] (A) Antibody response as assessed by microneutralization assay, and (B) inhibition of ACE2 binding. [Figure 8] Antigen-specific CD4 and CD8 T cell responses are shown. (A) S-specific CD4 T cell responses with peptide mix 1 (white bars) and peptide mix 2 (black bars). (B) S-specific CD8 T cell responses with peptide mix 1 (white bars) and peptide mix 2 (black bars). (C) N-specific CD4 T cell responses, and (D) N-specific CD8 T cell responses. [Figure 9] 1 is a series of graphical representations showing antigen-specific T cell induction by Co18, showing the net (antigen-specific) % cytokine-producing CD4 and CD8 T cells induced for (A) S1-specific CD4 T cells, (B) S1-specific CD8 T cells, (C) S2-specific CD4 T cells, (D) S2-specific CD8 T cells, and (E) N-specific CD4 T cells. [Figure 10-1] A series of graphical representations showing (A) the net % antigen-specific CD4+ response, (B) the net % antigen-specific CD8+ response, and the normalized frequency of (C) antigen-specific CD4 responses, and (D) antigen-specific CD8 responses. [Figure 10-2] A series of graphical representations showing (A) the net % antigen-specific CD4+ response, (B) the net % antigen-specific CD8+ response, and the normalized frequency of (C) antigen-specific CD4 responses, and (D) antigen-specific CD8 responses. [Table A] [Table B] [Table C] DETAILED DESCRIPTION OF THE INVENTION
[0563] General Throughout this specification, unless specifically stated otherwise or the context requires otherwise, references to a single step, composition of matter, group of steps, or group of compositions of matter shall be interpreted as encompassing one and more (i.e., one or more) of that step, composition of matter, group of steps, or group of compositions of matter.
[0564] Those skilled in the art will understand that the present disclosure is susceptible to variations and modifications other than those specifically described. The present disclosure should be understood to include all such variations and modifications. The present disclosure also includes all of the steps, features, compositions, and compounds referred to or indicated herein, individually or collectively, and any and all combinations or any two or more of such steps or features.
[0565] The present disclosure is not to be limited in scope by the specific examples described herein, which are intended for the purpose of illustration only. Functionally equivalent products, compositions, and methods are clearly within the scope of the present disclosure.
[0566] Any embodiment of the present disclosure herein shall be construed as applying mutatis mutandis to any other embodiment of the present disclosure, unless expressly stated otherwise. In other words, any specific embodiment of the present disclosure may be combined with any other specific embodiment of the present disclosure (except where mutually exclusive).
[0567] Any embodiment of the present disclosure disclosing a particular feature, or group of features, or method, or method step, is done so as to provide explicit support for disclaiming the particular feature, or group of features, or method, or method step.
[0568] Unless otherwise defined, all technical and scientific terms used herein shall be construed to have the same meaning as commonly understood by one of ordinary skill in the art (e.g., cell culture, molecular genetics, immunology, immunohistochemistry, protein chemistry, and biochemistry).
[0569] Unless otherwise indicated, the recombinant protein, cell culture, and immunological techniques utilized in the present disclosure are standard procedures, well known to those skilled in the art. Such techniques are described in J. Perbal, A Practical Guide to Molecular Cloning, John Wiley and Sons (1984), J. Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1989), T.A. Brown (editor), Essential Molecular Biology: A Practical Approach, Volumes 1 and 2, IRL Press (1991), D.M.G. Lover and B.D.H. Memes (editors), DNA Cloning: A Practical Approach, Volumes 1-4, IRL Press (1995 and 1996), and F.M.A. Usubel et al. (editors), Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience (1988, including all updates to date), Ed. Harlow and David Lane (editors), Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, (1988), and J.E. Coligan et al. al. (editors) Current Protocols in Immunology, John Wiley & Sons (including all updates to date).
[0570] The term "and / or," e.g., "X and / or Y," shall be understood to mean either "X and Y" or "X or Y," and shall be interpreted as providing explicit support for both meanings or for either meaning.
[0571] Throughout this specification the word "comprise" or variations such as "comprises" or "comprising" will be understood to imply the inclusion of the specified element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
[0572] As used herein, the term "derived from" shall be interpreted to indicate that a particular integer may be obtained from a particular source, but not necessarily directly from that source. Similarly, the term "based on" shall be interpreted to indicate that a particular integer may be developed or used from a particular source, but not necessarily directly from that source.
[0573] Selected Definition As used herein, the term "multicistronic" (also known as "polycistronic") with respect to polynucleotides, RNA, cRNA, and / or self-replicating RNA refers to RNA that encodes more than one polypeptide. The term encompasses "bicistronic" (or "dicistronic," i.e., encoding two polypeptides) and "tricistronic" (i.e., encoding three polypeptides) molecules. "Bicistronic" refers to a single nucleic acid that can encode two different polypeptides from different regions of the nucleic acid.
[0574] As used herein, the term "conventional mRNA" or "cRNA" or "unamplified RNA" refers to RNA that is a construct that allows for the expression of heterologous RNA and proteins, but that cannot be amplified within a host cell.
[0575] As used herein, the term "self-replicating RNA" refers to an RNA virus-based construct that has been engineered to allow expression of heterologous mRNA and proteins. The self-replicating RNA (e.g., in the form of naked RNA) can be amplified within a host cell and result in expression of a desired gene product within the host cell.
[0576] The term "naked" as used herein refers to a nucleic acid that is substantially free of other macromolecules, such as lipids, polymers, and proteins. Naked nucleic acids, such as self-replicating RNA, are not formulated with other macromolecules to improve cellular uptake. Thus, naked nucleic acids are not encapsulated in, adsorbed to, or bound to lipid nanoparticles (LNPs), liposomes, polymeric microparticles, or oil-in-water emulsions.
[0577] As used herein, the term "nucleotide sequence" or "nucleic acid sequence" will be understood to mean a series of contiguous nucleotides (or bases) covalently linked to a phosphodiester backbone. By convention, sequences are presented from the 5' to the 3' end unless otherwise specified. To facilitate clear description of nucleic acids, particular sequence components will be referred to as, for example, a "first nucleotide sequence" and a "second nucleotide sequence." It should be understood that the first and second sequences can appear in any desired order or orientation unless otherwise specified, and that no particular order or orientation is intended by the words "first," "second," etc.
[0578] As used herein, the term "antigen" refers to a molecule or structure containing one or more epitopes that induce, elicit, augment, or boost a cellular and / or humoral immune response. Antigens can include, for example, proteins and peptides derived from pathogens such as viruses, bacteria, fungi, protozoa, plants, or from tumors.
[0579] As used herein, the term "operably linked to" refers to the positioning of a subgenomic promoter or regulatory element (e.g., an IRES) relative to a nucleic acid such that expression of the nucleic acid is controlled or regulated by the element. For example, a subgenomic promoter can be operably linked to multiple nucleic acids via another regulatory element, such as, for example, an internal ribosome entry site (IRES).
[0580] As used herein, the term "subgenomic promoter" (also known as a "junction region" promoter) refers to a promoter that directs the expression of a heterologous nucleotide sequence and regulates protein expression.
[0581] As used herein, the term "internal ribosome entry site" or "IRES" refers to a sequence of nucleotides within an mRNA to which a ribosome or a component thereof, such as the 40S subunit of the ribosome, can bind. An IRES does not necessarily contain a nucleic acid (e.g., an initiation codon; AUG) that directs translation of the mRNA.
[0582] The term "polypeptide" or "polypeptide chain" will be understood to mean a series of consecutive amino acids linked by peptide bonds. For example, a protein shall be understood to include a single polypeptide chain, i.e., a series of consecutive amino acids linked by peptide bonds, or a series of polypeptide chains covalently or non-covalently bonded to one another (i.e., a polypeptide complex). A series of polypeptide chains may be covalently linked using suitable chemical bonds or disulfide bonds. Examples of non-covalent bonds include hydrogen bonds, ionic bonds, van der Waals forces, and hydrophobic interactions.
[0583] The term "recombinant" shall be understood to mean the product of artificial genetic recombination.
[0584] As used herein, the term "substantially the same" with respect to levels of expression means that the first and second antigens have (at least) levels of expression that are about 10% or less of each other.
[0585] As used herein, the terms "disease," "disorder," or "condition" refer to a disruption of or interference with normal function and include diseases or disorders, without being limited to any particular condition.
[0586] As used herein, a subject "at risk" of developing a disease or condition may or may not have detectable disease or disease symptoms, and may or may not exhibit detectable disease or disease symptoms prior to treatment according to the present disclosure. "At risk" indicates that the subject has one or more risk factors, which are measurable parameters that correlate with development of a disease or condition, as known in the art and / or described herein.
[0587] As used herein, the terms "treating," "treat," or "treatment" include administering an RNA or composition described herein, thereby reducing or eliminating at least one symptom of a particular disease or condition.
[0588] As used herein, the terms "preventing," "prevent," or "prevention" include providing prophylaxis against the occurrence or recurrence of a particular disease or condition in an individual. An individual may be predisposed to or at risk for developing the disease, but has not yet been diagnosed with the disease.
[0589] As used herein, the phrase "delaying the progression of" includes reducing or slowing the progression of a disease or condition, and / or at least one symptom of a disease or condition, in an individual.
[0590] An "effective amount" refers to at least an amount effective at a dosage and for a period of time necessary to achieve a desired result. For example, the desired result may be a therapeutic or prophylactic result. An effective amount may be provided in one or more administrations. In some embodiments of the present disclosure, the term "effective amount" refers to an amount necessary to effect treatment of a disease or condition as described above. In some embodiments of the present disclosure, the term "effective amount" refers to an amount necessary to effect changes associated with a disease or condition as described above. An effective amount may vary depending on the disease or condition being treated or the factors being modified, as well as on the body weight, age, ethnic background, sex, health and / or physical condition, and other factors associated with the mammal being treated. Typically, an effective amount will fall within a relatively broad range (e.g., a "dosage" range) that can be determined through routine testing and experimentation by a physician. Therefore, the term should not be construed to limit the present disclosure to a specific amount, e.g., weight or number of RNAs. An effective amount may be administered in a single dose or in one or more repeated doses over a treatment period.
[0591] A "therapeutically effective amount" is at least the minimum concentration required to effect a measurable improvement in a particular disease or condition. The therapeutically effective amount herein may vary depending on factors such as the patient's disease state, age, sex, and weight, as well as the ability of the RNA of the present disclosure to induce a desired response in an individual. A therapeutically effective amount is also one in which any toxic or harmful effects of the RNA are outweighed by the therapeutically beneficial effects.
[0592] As used herein, the term "prophylactically effective amount" shall be taken to mean an amount of RNA of the present disclosure sufficient to prevent or inhibit or delay the onset of one or more detectable symptoms of a disease or disorder as described herein.
[0593] As used herein, the term "subject" shall be taken to mean any animal, including a human, e.g., a mammal. Exemplary subjects include, but are not limited to, humans and non-human primates. For example, the subject is a human.
[0594] As used herein, the term "lipid nanoparticle" or "LNP" shall be understood to refer to a lipid-based particle having at least one dimension on the order of nanometers (e.g., 1-1,000 nm) and comprising a compound of any formula described herein. In embodiments, LNPs are formulated in compositions for delivery of polynucleotides to desired targets, such as cells, tissues, organs, tumors, etc. For example, lipid nanoparticles or LNPs refer to any lipid composition, including, but not limited to, those selected from liposomes or vesicles, in which an aqueous volume is encapsulated by an amphiphilic lipid bilayer (e.g., single; unilamellar, or multiple; multilamellar) micelle-like lipid nanoparticles having a non-aqueous core and solid lipid nanoparticles, which lack a lipid bilayer.
[0595] Polynucleotides As used herein, the term "polynucleotide" refers to a molecular chain of nucleotides chemically linked by a series of ester linkages between the phosphoryl group of one nucleotide and the hydroxyl group of the sugar in an adjacent nucleotide. In one example, the polynucleotide is DNA. In one example, the polynucleotide is RNA, e.g., mRNA. For example, the mRNA may be conventional mRNA (cRNA) or self-replicating RNA.
[0596] As used herein, the term "fragment" refers to a portion of a nucleotide sequence or polypeptide of a reference nucleotide sequence or polypeptide disclosed herein that maintains a defined activity of the full-length nucleotide sequence or polypeptide.
[0597] As used herein, the term "variant" refers to a nucleotide sequence having one or more substitutions, insertions, deletions, and / or other modifications compared to the unmodified sequence. It will be apparent to one of skill in the art that any variant described herein will have the same or similar expression of the encoded protein. For example, the variant is a functional variant. Exemplary modifications to the nucleotide sequence and / or polypeptide will be apparent to one of skill in the art and / or are described herein.
[0598] In one embodiment, the modification is a chemical modification of one or more nucleotides of the nucleotide sequence, for example, at least one naturally occurring nucleotide of the polynucleotide is replaced with a chemically modified nucleotide (e.g., pseudouridine (ψ) and 1-methylpseudouridine (m1ψ)).
[0599] In one embodiment, the modification comprises increasing the G / C content of the nucleotide sequence.
[0600] In one embodiment, the modification comprises codon optimization of the nucleotide sequence.
[0601] In one embodiment, the substitution is a conservative substitution. One skilled in the art will understand that a conservative substitution with respect to a polypeptide involves replacing an amino acid in a polypeptide with a different amino acid that has similar biochemical properties (e.g., charge, hydrophobicity, and size). In one embodiment, the substitution is a non-conservative substitution.
[0602] As used herein, the terms "encode," "encodes," or "encoding" refer to a region of a polynucleotide that can be translated into a polypeptide.
[0603] Polynucleotides of the present disclosure include DNA and RNA (e.g., mRNA).
[0604] Deoxyribonucleic acid (DNA) In one example, the polynucleotide is DNA (eg, a DNA vector).
[0605] It will be apparent to one skilled in the art that the DNA of the present disclosure further comprises an endonuclease restriction site at the 3' end of the 3' UTR. One skilled in the art will understand that the endonuclease restriction site allows for the insertion of one or more nucleotide sequences (e.g., encoding an antigen of interest, fragments and / or variants thereof) without destroying the remainder of the DNA.
[0606] As used herein, the term "restriction endonuclease site" refers to a sequence of DNA that binds to a restriction endonuclease. Typically, a restriction endonuclease site is a short sequence (e.g., approximately 4-8 base pairs) that is recognized and cleaved by a restriction endonuclease.
[0607] As used herein, the terms "restriction enzymes" or "restriction endonucleases" refer to a class of enzymes that occur naturally in bacteria and some viruses. Restriction endonucleases specifically bind to and cut double-stranded DNA at a particular site within or adjacent to the restriction endonuclease site. Exemplary restriction endonucleases include, for example, BciVI (Bful), Bcul (Spel), EcoRI, Aatll, AgeI (BshTI), Apal, BamHI, BglII, Blpl (Bpu1102I), BsrGI (Bsp1407), Clal (Bsu15I), EcoRI, EcoRV (Eco32I), Eam1104I (EarI), Hindlll, Kpnl, Mlul, Ncol, Ndel, Nhel, Notl, Nsil, Mph1103I), Pstl, Pvul, Pvull, SacI, SalI, ScaI, SpeI, Xbal, Xhol, Sacll (Cfr42I), and Xbal.
[0608] In one example, the present disclosure provides a transcribable polynucleotide comprising a first nucleotide sequence encoding a first antigen of interest and a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES. For example, the polynucleotide is a DNA plasmid comprising the first and second nucleotide sequences and, optionally, one or more nucleotide sequences encoding the one or more antigens of interest.
[0609] In one embodiment, the DNA comprises a nucleotide sequence containing a restriction endonuclease site located 3' of the 3' UTR. The presence of the restriction endonuclease site located 3' of the 3' UTR allows for the production of linearized DNA. Linearization of the DNA ensures defined termination of the in vitro transcribed DNA to produce mRNA.
[0610] Ribonucleic acid (RNA) In one example, the polynucleotide is an mRNA comprising, in 5' to 3' order, a first nucleotide sequence encoding a first antigen of interest and a second nucleotide sequence encoding a second antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0611] mRNA of the present disclosure encompasses non-replicating mRNA (also referred to as conventional mRNA (cRNA) or non-amplified) and self-replicating RNA (also referred to as self-amplifying RNA or sa-mRNA).
[0612] Conventional (non-replicating) RNA The present disclosure provides multicistronic cRNAs.
[0613] Those skilled in the art will understand that the cRNA of the present disclosure comprises, in 5' to 3' order, a 5' cap structure, a 5'-UTR, fragments and / or variants thereof, a first nucleotide sequence encoding a first antigen of interest, a second nucleotide sequence encoding a second antigen of interest, a 3'-UTR, and a 3' tailing sequence (e.g., a polyadenylation signal or one or more polyA tails). The cRNA of the present disclosure may further comprise a translational internal ribosome entry site (e.g., a Kozak consensus sequence or IRES) operably linked to the first antigen of interest.
[0614] self-replicating RNA The present disclosure provides multicistronic self-replicating RNAs (also known as replicons).
[0615] Those skilled in the art will understand that the self-replicating RNA of the present disclosure is based on the genomic RNA of an RNA virus. The RNA should be positive (+) strand so that it can be directly translated after delivery to a cell without the need for an intervening replication step (e.g., reverse transcription). Translation of the RNA results in the production of nonstructural proteins (NSPs) that combine to form a replicase complex (i.e., RNA-dependent RNA polymerase). The complex then amplifies the original RNA, producing both antisense and sense transcripts, resulting in the production of multiple daughter RNAs that can then be translated and transcribed, enhancing overall protein expression.
[0616] In one example, a self-replicating RNA of the present disclosure comprises nonstructural proteins, 5' and 3' untranslated regions (UTRs), and a native subgenomic promoter of an RNA virus.
[0617] In one embodiment, the self-replicating RNA comprises one or more nonstructural proteins of an RNA virus. For example, the RNA comprises at least one gene selected from the group consisting of a viral replicase (or viral polymerase), a viral protease, a viral helicase, and other nonstructural viral proteins. For example, the self-replicating RNA comprises a viral replicase (or viral polymerase).
[0618] In another embodiment, the self-replicating RNA comprises a 5'-terminal UTR and a 3'-terminal UTR of an RNA virus. It will be apparent to those skilled in the art that the terms 5' and 3' UTR also encompass the terms 5' and 3' conserved sequence elements (CSEs). In one embodiment, the self-replicating RNA comprises a 5'-terminal CSE and a 3'-terminal CSE.
[0619] The self-replicating RNA of the present disclosure is not capable of inducing the production of infectious viral particles, for example, the self-replicating RNA of the present disclosure does not contain viral genes encoding structural proteins necessary for the production of viral particles.
[0620] In one example, the self-replicating RNA is derived from or based on an alphavirus. Suitable alphaviruses will be apparent to those of skill in the art and / or are described herein.
[0621] In another example, the self-replicating RNA is derived from or based on a virus other than an alphavirus, e.g., a positive-stranded RNA virus. Suitable positive-stranded RNA viruses suitable for use in the present disclosure will be apparent to those of skill in the art and include, for example, a picornavirus, flavivirus, rubivirus, pestivirus, hepacivirus, calicivirus, or coronavirus.
[0622] Alphaviruses In one example, the self-replicating RNA of the present disclosure is derived from (or based on) an alphavirus.
[0623] Alphaviruses are the only genus in the Togaviridae family and are enveloped viruses with a positive-sense, single-stranded RNA genome. Those skilled in the art will understand that an alphavirus genome contains two open reading frames (ORFs): nonstructural and structural. The first ORF encodes four nonstructural proteins (NSP1, NSP2, NSP3, and NSP4) required for viral RNA transcription and replication. The second encodes three structural proteins: the core nucleocapsid protein C, and the envelope proteins P62 and E1, which assemble as a heterodimer. Viral membrane-anchored surface glycoproteins are involved in receptor recognition and entry into target cells via membrane fusion.
[0624] In one example, the self-replicating RNA of the present disclosure comprises a viral replicase (or viral polymerase). For example, the viral replicase is an alphavirus replicase, such as the alphavirus protein NSP4.
[0625] In one example, the self-replicating RNA of the present disclosure does not encode one or more alphavirus structural proteins (e.g., capsid and / or envelope glycoproteins), e.g., the self-replicating RNA is incapable of producing RNA-containing alphavirus virions (i.e., infectious virus particles).
[0626] In one example, the self-replicating RNA comprises a native alphavirus SG promoter, e.g., a native alphavirus SG promoter, which is a minimal SG promoter (i.e., the minimal sequence required for initiation of transcription), comprising the sequence set forth in SEQ ID NO:1.
[0627] Those of skill in the art will recognize alphaviruses suitable for use in the present disclosure. Exemplary alphaviruses include, but are not limited to, Venezuelan equine encephalitis virus (VEE; e.g., Trinidad donkey, TC83CR), Semliki Forest virus (SFV), Sindbis virus (SIN), Ross River virus, Western equine encephalitis virus, Eastern equine encephalitis virus, Chikungunya virus, SAAR86 virus, Everglades virus, Mucambo virus, Barmah Forest virus, Middleburg virus, Pixuna virus, O'nyong-nyong virus, Getah virus, Sagiyama virus, Bebaru virus, Mayaro virus, Una virus, Aura virus, Wataroa virus, Banbanki virus, Kyzylagach virus, Highland J virus, Fort Morgan virus, Nudum virus, and Boggy Creek virus. The term alphavirus also includes chimeric alphaviruses, which contain genomic sequences from more than one alphavirus (eg, as described by Perri et al., (2003) J. Virol. 77(19):10394-403).
[0628] Regulatory elements The present disclosure provides a polynucleotide comprising a first nucleotide sequence encoding a first antigen of interest, and a second nucleotide sequence encoding the sequence antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0629] The present disclosure provides an RNA (e.g., a cRNA or a self-replicating RNA) comprising a first nucleotide sequence encoding a first antigen of interest, and a second nucleotide sequence encoding the sequence antigen of interest operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.
[0630] In one example, the first antigen of interest is operably linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof.
[0631] The present disclosure provides a self-replicating RNA comprising a first nucleotide sequence encoding a first antigen operably linked to a subgenomic (SG) promoter, and a second nucleotide sequence encoding a second antigen operably linked to a promoter regulatory element selected from the group consisting of an SG promoter and an internal ribosome entry site (IRES).
[0632] Kozak consensus sequence As used herein, the term "Kozak consensus sequence" refers to a nucleotide sequence identified in eukaryotic genes that contains a start codon (also called a translation initiation codon) that is recognized by the ribosome, thereby facilitating translation of the gene.
[0633] Exemplary Kozak consensus sequences are known in the art and / or described herein. In one example, the Kozak consensus sequence is set forth in SEQ ID NO: 38. In another example, the Kozak consensus sequence is set forth in SEQ ID NO: 39. In one example, the Kozak consensus sequence is ACCATGG. In another example, the Kozak consensus sequence is ACCATG.
[0634] Subgenomic promoter Suitable SG promoters (also known as "junction region" promoters) for use in the present disclosure will be apparent to those of skill in the art and / or are described herein.
[0635] In one embodiment, the SG promoter is derived from or based on an alphavirus SG promoter. For example, the SG promoter is a native alphavirus SG promoter. In one embodiment, the native SG promoter is a minimal SG promoter. For example, a minimal SG promoter is the minimal sequence required for initiation of transcription. In one embodiment, the native SG promoter is an extended SG promoter. For example, an extended SG promoter is a minimal SG promoter extended at the 5' end by nucleotides occurring in a sequence encoding a nonstructural protein (e.g., NSP4) of an RNA virus (e.g., an alphavirus). In one embodiment, the extended SG promoter is a minimal SG promoter extended at the 5' end by nucleotides occurring in a sequence encoding an alphavirus NSP4.
[0636] In one example, a polynucleotide of the disclosure comprises an SG promoter from any alphavirus. For example, an RNA (e.g., a cRNA or a self-replicating RNA) of the disclosure comprises an SG promoter from any alphavirus.
[0637] In one example, the self-replicating RNA comprises the SG promoter from any alphavirus.
[0638] The polynucleotide of the present disclosure comprises two or more nucleotide sequences encoding two or more antigens of interest. In one embodiment, the two or more nucleotide sequences are each operably linked to an SG promoter. When two or more SG promoters are present in the RNA of the present disclosure, the promoters may be the same or different. For example, the two or more SG promoters are derived from the same alphavirus. In another embodiment, the two or more SG promoters are derived from different alphaviruses.
[0639] When two or more SG promoters are present in a self-replicating RNA of the present disclosure, the promoters can be the same or different. For example, the two or more SG promoters are derived from the same alphavirus. In another example, the two or more SG promoters are derived from different alphaviruses.
[0640] Internal ribosome entry site (IRES) Suitable IRESs for use in the present disclosure will be apparent to one of skill in the art and / or are described herein.
[0641] In one example, the IRES is derived from an encephalomyocarditis virus (EMCV), for example, the IRES is a wild-type IRES from EMCV. ...
Claims
1. A multicistronic self-replicating RNA having, in 5' to 3' order: a) a first nucleotide sequence encoding a first antigen operably linked to a subgenomic (SG) promoter; and b) a multicistronic self-replicating RNA comprising a second nucleotide sequence encoding a second antigen operably linked to a regulatory element selected from the group consisting of an SG promoter and an internal ribosome entry site (IRES).
2. The multicistronic self-replicating RNA of claim 1, wherein the RNA comprises one or more additional nucleotide sequences, each encoding an additional antigen operably linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and the one or more nucleotide sequences are located 3' to the second nucleotide sequence. (i) the SG promoter is a minimal SG promoter or an extended SG promoter, the extended SG promoter being extended at the 5' end by nucleotides occurring in a sequence encoding a nonstructural protein of an RNA virus; and / or (ii) The multicistronic self-replicating RNA of claim 1 or 2, wherein the IRES is a wild-type IRES derived from encephalomyocarditis virus (EMCV).
4. The RNA is, in order from 5' to 3', a) a first nucleotide sequence encoding a first antigen operably linked to a minimal SG promoter, and a second nucleotide sequence encoding a second antigen operably linked to a minimal SG promoter; or b) a first nucleotide sequence encoding a first antigen operably linked to a minimal SG promoter and a second nucleotide sequence encoding a second antigen operably linked to an extended SG promoter; or c) a first nucleotide sequence encoding a first antigen operably linked to a minimal SG promoter, and a second nucleotide sequence encoding a second antigen operably linked to a wild-type EMCV IRES. (i) the minimal SG promoter comprises a sequence set forth in SEQ ID NO:1; (ii) the extended SG promoter comprises a sequence set forth in SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:47; and / or (iii) The multicistronic self-replicating RNA of claim 3, wherein the wild-type EMCV IRES comprises the sequence set forth in SEQ ID NO:
4.
6. The multicistronic self-replicating RNA of claim 1 or 2, wherein the self-replicating RNA is derived from an alphavirus, the alphavirus being selected from the group consisting of Semliki Forest virus (SFV), Sindbis virus (SIN), and Venezuelan equine encephalitis virus (VEE), and combinations thereof.
7. The multicistronic self-replicating RNA of claim 1 or 2, wherein the antigen is a viral antigen derived from a respiratory virus, the respiratory virus being selected from the group consisting of influenza virus, respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, coronavirus, adenovirus, and bocavirus. (i) the antigens are from different strains of the influenza virus; and / or (ii) The multicistronic self-replicating RNA of claim 7, wherein the antigens are derived from different subtypes of the influenza virus. (i) the antigen is an influenza virus hemagglutinin (HA) protein, neuraminidase (NA) protein, matrix (M) protein, nucleoprotein (NP), and / or nonstructural (NS) protein; and / or (ii) The multicistronic self-replicating RNA of claim 7, wherein the antigen is an H5 protein and / or an N1 protein.
10. The RNA is, in order from 5' to 3', a) a first nucleotide sequence encoding the H5 protein and a second nucleotide sequence encoding the N1 protein; or 10. The multicistronic self-replicating RNA of claim 9, comprising: b) a first nucleotide sequence encoding the N1 protein and a second nucleotide sequence encoding the H5 protein.
11. 8. The multicistronic self-replicating RNA of claim 7, wherein the coronavirus is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the antigen is SARS-CoV-2 nucleocapsid (N) protein and / or spike (S) protein.
12. The RNA is, in order from 5' to 3', a) a first nucleotide sequence encoding the N protein, and a second nucleotide sequence encoding the S protein; or 12. The multicistronic self-replicating RNA of claim 11, comprising: b) a first nucleotide sequence encoding the S protein and a second nucleotide sequence encoding the N protein.
13. The multicistronic self-replicating RNA of claim 1 or 2, wherein the RNA is encoded by a sequence set forth in any one of SEQ ID NOs: 10 to 14, or SEQ ID NOs: 19 to 27, or SEQ ID NOs: 30 to 31.
14. An immunogenic composition comprising a self-replicating RNA according to any one of claims 1 or 2, and comprising a plurality of multicistronic self-replicating RNAs according to claims 1 or 2, each multicistronic self-replicating RNA encoding a different polypeptide antigen sequence.
15. A pharmaceutical composition comprising the immunogenic composition of claim 14 and a pharma- ceutically acceptable carrier, and further comprising a lipid nanoparticle (LNP), a polymeric microparticle, or an oil-in-water emulsion, wherein the self-replicating RNA is encapsulated in, bound to, or adsorbed to the LNP, polymeric microparticle, or oil-in-water emulsion.
16. A pharmaceutical composition for treating or preventing, or delaying the progression of, a disease or condition in a subject in need thereof, or for inducing an immune response in a subject in need thereof, comprising a self-replicating RNA described in claim 1 or 2. (i) the disease or condition is a respiratory viral infection, and the respiratory viral infection is selected from the group consisting of influenza, influenza virus infection, bronchiolitis, pneumonia, croup, SARS-CoV-2 infection, COVID-19, ARDS, and combinations thereof; and / or (ii) The pharmaceutical composition according to claim 16, wherein the immune response is a humoral and / or cell-mediated immune response.
18. A polynucleotide encoding the self-replicating RNA of claim 1 or 2, which is a recombinant DNA that is a plasmid.
19. The RNA comprises, in order from 5' to 3', (i) a first nucleotide sequence encoding an influenza virus hemagglutinin (HA) protein operably linked to an SG promoter, and a second nucleotide sequence encoding a neuraminidase (NA) protein operably linked to an extended SG promoter; or (ii) a first nucleotide sequence encoding a neuraminidase (NA) protein operably linked to an SG promoter, and a second nucleotide sequence encoding an influenza virus hemagglutinin (HA) protein operably linked to an extended SG promoter. Including, 3. The multicistronic self-replicating RNA of claim 1, wherein the extended SG promoter is extended at the 5' end by nucleotides occurring in a sequence encoding a nonstructural protein of an RNA virus.
20. The RNA, in order from 5' to 3', (i) a first nucleotide sequence encoding an influenza virus hemagglutinin (HA) protein operably linked to an SG promoter comprising the sequence set forth in SEQ ID NO:1, and a second nucleotide sequence encoding a neuraminidase (NA) protein operably linked to an extended SG promoter comprising the sequence set forth in SEQ ID NO:2; or (ii) a first nucleotide sequence encoding a neuraminidase (NA) protein operably linked to an SG promoter comprising the sequence set forth in SEQ ID NO:1, and a second nucleotide sequence encoding an influenza virus hemagglutinin (HA) protein operably linked to an extended SG promoter comprising the sequence set forth in SEQ ID NO:
2. The multicistronic self-replicating RNA of claim 1 .
